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SUMMARY
The goal of this thesis is to develop a general tool for disease progression modeling
which can handle arbitrary observation times, support a multi-dimensional (M-D)
view of progression as the co-evolution of multiple interacting biomarkers, capture
complex nonlinear patterns, and provide visualizations that effectively communicate
the dynamics of disease to domain experts. The development of an M-D view of
disease progression is important since many diseases are characterized by several
temporally-evolving processes in structure, function, and biochemical, whose interac-
tion can reveal critical but previously undiscovered mechanism.
The Continuous-time hidden Markov model (CT-HMM) is a useful tool in mod-
eling disease progression based on noisy observations of disease states which arrive at
irregular sample times. Unfortunately, the modeling flexibility provided by the CT-
HMM comes at the cost of a more complex inference procedure than the standard
discrete-time HMM. There is no widely-accepted algorithm for efficient parameter
learning in the existing literature, and numerical optimization is often utilized di-
rectly in maximum likelihood estimation. This has restricted the use of CT-HMM
to small models or to applications that make restrictive assumptions on the state
transition timing.
In this thesis, we propose to use CT-HMM with M-D gridded state structure to
model disease progression, where each dimension represents the change of one or a
set of disease markers. By learning dynamic interactions from longitudinal datasets,
progression trajectories and patterns can be explored and visualized in the full spec-
trum of disease evolution, leading to greater insights into population level behavior,
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enabling prediction of future progression, and the identification of phenotypes. The
development of M-D CT-HMM models for large state spaces requires the development
of efficient parameter learning methods.
We present the first complete characterization of Expectation-Maximization (EM)-
based learning methods in CT-HMM, which both extends and unifies prior work on
continuous-time Markov chain (CTMC) models. We address two technical challenges:
the estimation of posterior state probabilities, and the computation of end-state con-
ditioned statistics in a CTMC. We efficiently discretize the estimation of posterior
state probabilities into a discrete time-inhomogeneous HMM, and present soft and
hard EM algorithms. The benefits and drawbacks of these developed methods are an-
alyzed and experimentally validated relative to the existing literature. For CT-HMM
hidden path decoding, we present a novel method for computing the path-conditioned
expected state duration, which are useful in trajectory decoding and clustering tasks.
Our M-D CT-HMM methods are evaluated on three real-world datasets from
Glaucoma, Alzheimer’s disease, and Hypertension, with applications including vi-
sualizations of the progression, prediction of future measurements, and trajectory
clustering. The visualization results of disease progression provide a novel insight
into the global structure of progression, and the prediction results outperform the
state-of-the-art method for Glaucoma. Our promising results demonstrate that M-D
CT-HMM paired with visualizations can provide insights into disease evolution and





Thesis Statement Continuous-time hidden Markov model with multi-dimensional
state structure can model disease progression as the co-evolution of multiple
biomarkers and support visualizations of complex dynamics, leading to greater
insights into population level behavior, enabling prediction of future progression
and the identification of phenotypes.
The goal of disease progression modeling is to learn a model for the temporal evo-
lution of a disease from longitudinal clinical measurements obtained from a sample of
patients. By distilling population data into a compact representation, disease progres-
sion models can yield insights into the disease process through the visualization and
analysis of disease progression trajectories (see Fig. 1,2 for an example). In addition,
disease models can be utilized to predict the future course of disease in an individual,
supporting the development of individualized treatment schedules with improved ef-
ficiencies. Progression models can also support phenotyping by providing a similarity
measure between trajectories for grouping patients based on their progression.
Hidden Markov model (HMM) is an attractive choice for modeling disease pro-
gression for three reasons: (1) it supports the abstraction of a disease state which
is useful to model staged progression with complex dynamics; (2) it can deal with
noisy measurements effectively by using data emission models from states and lever-
aging population transition behavior; (3) it can easily incorporate dynamical priors
and model structural constraints. The conventional discrete-time HMMs have been
used to model disease progression [91], but they are not suitable in general because





















Figure 1: A 2-dimensional state structure for Glaucoma progression modeling, for
capturing the interaction between structural and functional degeneration. The arrows
represent the allowed instantaneous transitions.
state transitions can only happen at these discrete times. In reality patient visits
are frequently irregular in time, as a consequence of scheduling issues, missed visits,
and changes in symptomatology, and the underlying disease process also evolves in
continuous, arbitrary time.
A Continuous-time HMM (CT-HMM) is an HMM in which the transitions be-
tween hidden states can occur at arbitrary continuous times, and the observational
data can also arrive irregularly in time [16] . It is therefore more suitable for mod-
eling disease process and the clinical measurements. In this dissertation, we propose
to use CT-HMM with multi-dimensional (M-D) gridded state structure (an example
2-D model is in Fig. 1) to model disease progression, where each dimension repre-
sents the change of one or a set of biomarkers. By using M-D gridded disease states
defined by M kinds of disease progression aspects (such as structural, functional,
biochemical, etc.) and learning their dynamic interactions over time from longitu-
dinal datasets, population-level progression trajectories can be explored in the full
spectrum of disease evolution. Furthermore, the learned model can be utilized to
predict future progression trajectory and find potential progressing phenotypes when
































(a) Glaucoma progression (b) Alzheimer's disease progression
Figure 2: Visualization scheme: (a) Glaucoma disease progression: the strongest
transition among the three instantaneous links from each state are shown in blue
while other transitions are drawn in dotted black. The line width and the node size
reflect the expected count. The node color represents the average sojourn time (red to
green: 0 to 5 years and above). (b) Alzheimern’s disease progression: the vis scheme
is similar to (a) but the strongest transition link from each state is color coded as
follows: Aβ direction only (blue), hippo only (green), cog only (red), Aβ + hippo
(cyan), Aβ+ cog (magenta), hippo+ cog (yellow), Aβ+hippo+ cog(black). The node
color represents the average sojourn time (red to green: 0 to 3 years and above).
One motivating application of our MD CT-HMMs is for modeling Glaucoma pro-
gression, which is characterized by two temporally-evolving processes: structural and
functional degeneration, and their relationship is clinically-found to be complex and
non-linear. There are conflicting findings in the temporal ordering of detectable struc-
tural and functional degeneration, which confound glaucoma clinical assessment and
treatment plans [97], resulting in inefficient treatment. We use a 2D state struc-
ture where one dimension is functional deterioration, and the other is structural
degeneration, for modeling Glaucoma progression (Fig. 1). Our model can flexibly
capture the nonlinear relationship between composite disease states, revealing subtle
dynamics that the conventional longitudinal model, such as linear regression, cannot
represent. Our learned 2D CT-HMM from longitudinal dataset can not only show
whether structural degeneration precedes functional loss in the early disease stages,
but can also reveal at what structural ranges the onset of functional degeneration
happen more frequently (Fig. 2(a)).
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Our M-D disease progression models bridges the gap between the simple 1-D stag-
ing models (mild to severe) usually used in clinics and the complex disease-specific
models often designed in research. The proposed M-D models generalize the con-
ventional 1-D staging models with more expressive power. For clinical use, the M-D
models with validated predictive power can be utilized to plan a cost-effective visiting
interval and to inform treatments. In research side, the results from our general-
purpose models can be used to generate hypotheses of the disease mechanism, and
aid the preliminary design of the more sophisticated disease-specific models. Our
M-D models paired with visualization function acts as a general exploratory tool for
studying the dynamics of a disease evolution from multiple biomarkers, complement-
ing other existing disease models.
We now turn to discuss the technical challenges in learning CT-HMM. Though
CT-HMM is a more suitable model than DT-HMM for disease modeling, unfortu-
nately the additional modeling flexibility provided by the CT-HMM comes at the
cost of a more complex inference procedure. In CT-HMM, not only are the hidden
states unobserved, but also their transition times are unobserved. It is also possi-
ble for multiple unobserved hidden state transitions to occur between two successive
observations. An early parameter estimation algorithm circumvents these challenges
in decoding hidden information by directly maximizing the data likelihood [29] using
standard numerical optimization. However, the general numerical methods, which
require calculation of derivatives of likelihood function, are not efficient enough for
learning large-scale CT-HMM models (we will show a complexity analysis shortly).
The lack of efficient learning algorithms in the literature has limited CT-HMM to
applications of small models [29] or for large-scale models requires unrealistic as-
sumptions on state transition timing [42, 52]. There is a need for learning methods
which can scale to large state space sizes.
With the challenges of learning CT-HMM, one may resort to simply discretize
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the time horizon and just use discrete-time HMM. However, the time horizon for
state changes in medical conditions can vary dramatically. In early stages of disease
a state change might not occur for years, but in an acute phase they could occur
very frequently. For states with very short expected dwelling times, the discrete time
step needs to be sufficiently small. However, this might be inefficient for dealing
with changes that occur once several years. On the other hand, if the discretization
is too coarse, many transitions could be collapsed into a single one, obscuring the
real dynamics in continuous-time. In contrast, CT model performs inference over
arbitrary timescales using a single matrix exponential. We believe CT is a better
choice than DT for modeling continuous-time processes such as disease progression
and clinical data.
To tackle the challenges of CT-HMM learning, if we consider a simpler case where
the hidden states can be observed directly without noise but only at irregularly-
sampled times, then the model is equivalent to a continuous-time Markov chain
(CTMC) model with incomplete observed data. Expectation-Maximization (EM)
algorithms for maximum likelihood estimation (MLE) in CTMC with incomplete ob-
servation was developed in [64]. It works by computing expected state durations and
state transition counts [7, 25] conditioned on each pair of successive state observations
in the E-step, and use these calculated sufficient statistics to update parameters in
the M-step.
In computing these conditioned expectations in CTMC, [64] finds that efficient
closed-form evaluations are obtained when the transition intensity matrix can be
diagonalized through an eigendecomposition (abbreviated as Eigen). Such an ap-
proach has been extended to CT-HMM [90] recently. However, the intensity matrix
is frequently not diagonalizable during learning, and this approach often fails in real
data [64]. More recently, [25] demonstrates that the necessary conditional expecta-
tions can also be computed using two alternative and more general approaches: matrix
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exponential (abbreviated as Expm) and uniformization (abbreviated as Unif ). Unfor-
tunately, none of these two methods have been explored or developed for CT-HMM,
which has the ability to correctly account for measurement noise and offers more
flexibility to clinicians in describing the relationship between measurements and the
true disease states.
In this dissertations, we present the first comprehensive framework for efficient
parameter learning in CT-HMM models, which both extends and unifies prior work
on CTMC models. Based on the finite number of observations, our framework dis-
cretizes the estimation of posterior state probabilities at observation times into a
time-inhomogeneous hidden Markov model, and then incorporates two approaches to
estimating the hidden state distributions for the corresponding observations. In the
“hard” approach, the distribution over hidden states is approximated by the single
most likely (Viterbi) decoding, which results in significant computational savings. The
“soft” approach, in contrast, maintains the full distribution over the hidden states,
gaining accuracy at the cost of increased computation. The benefits and drawbacks of
these approaches combined with the three different approaches (Expm, Unif, Eigen)
for computing the end-state conditional expectations [25] are analyzed and validated
experimentally both by simulation and by running on real-world disease longitudi-
nal datasets. We find that soft EM approach achieves higher accuracy and is more
robust to noises than hard EM. Expm in computing conditioned expectations works
best in soft EM while Unif can achieve the best efficiency in hard EM due to its
decomposability.
In addition to developing novel EM algorithms for CT-HMM parameter learning,
we also review and discuss the state sequence decoding problem in CT-HMM. The
decoding of the hidden states corresponding to the actual observations can be solved
using Viterbi algorithm by forming a time-inhomogenous embedded Markov chain.
However, the problem of solving the most probable state sequence in between two
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specified states with a total time, is unsolved until recently [46, 66]. Furthermore,
the problem of finding the globally most probable state sequence given a set of ir-
regularly observed measurements seems to still be an open question as there is no
prior literature. In this dissertation, we focus on exploring the simpler problems of
finding the optimal state sequence given two (decoded) end-states and a total time.
It is discovered recently in [66] that the problem of finding the best state sequence
marginaling out the state dwelling time is always well-defined while the solution of
the most likely state and duration trajectory does not always exist when the model
parameters have a found property [66].
For the well-defined problem of finding the optimal state sequence marginaling out
the dwell time given two end-states and a total time, [46] proposes a path extending
and pruning method which finds the exact best state sequence in finite time. We
augment this approach in also finding the expected state duration given the optimal
path and the total time, which we name it as computation of path-conditioned ex-
pected state duration. We show that the three methods (Eigen, Expm, Unif ) that
computes the end-state conditioned statistics, can also be used here by working on
an auxiliary matrix constructed for the path. We also derive a new closed-form based
on Laplace transform to compute these durations with better time complexity than
the above methods but with the prerequisite that the holding time parameters are
distinct. We compare the time complexity of all methods and gives simulation results.
The developed decoding methods can be utilized to understand the most probable
hidden transition dynamics and in trajectory clustering tasks.
In application domains, we utilize a 2-D CT-HMM for Glaucoma progression
modeling in structural and functional dimension. Our results supports the finding
in [95] that retinal nerve fiber layer (RNFL) thickness of around 77 microns acts as
a tipping point at which functional deterioration became clinically observable with
structural deterioration. In addition to qualitative visualization, we devise a simple
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procedure for predicting future continuous measurements using the learned model.
Our 2D CT-HMM gives better prediction results than the state-of-the art method
using Bayesian joint linear regression [62] for Glaucoma, which shows the practical
value of CT-HMM for effective disease prognosis and management.
Besides conducting detailed analysis for Glaucoma progression modeling, we also
do a preliminary study for Alzheimer’s disease using 3-D CT-HMM with structural,
functional, and biochemical markers, and a 2-D blood pressure longitudinal analysis
for Hypertension using a 2-D CT-HMM on Electronic Health Record (EHR) data.
Our preliminary results in Alzheimer’s disease corroborates the recent finding that
Amyloid β (Aβ) is an early marker before detectable cognition decline and structural
loss [17]. For hypertension, our trajectory analysis finds two distinct progression
clusters and their visualization clearly show the different transition trends, which
demonstrate the potential use of our model for finding progression phenotypes.
This dissertation is organized as follows. Chapter 2 reviews the related state-
based disease progression models and compare them to our M-D CT-HMM. Chapter
3 presents the proposed framework and novel EM algorithms for CT-HMM param-
eter learning with experimental results from simulations and on real-world disease
datasets. Chapter 4 reviews the literature for decoding the hidden optimal state
sequence given two end-states and a total time, and then presents our methods for
computing path-conditioned expected state durations with analysis and simulation
results. Chapter 5 gives detailed analysis and prediction results for Glaucoma pro-
gression modeling, and Chapter 6 shows preliminary studies for Alzheimer’s disease
and Hypertension. Finally Chapter 7 gives conclusion and discusses future directions.
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Table 1: Time complexity comparison of all presented methods in evaluating the
required expectations under Soft/Hard EM for CT-HMM learning (r: number of
distinct time interval, S: number of states, L: number of edges, V : number of visits,
M : the truncation point for Unif, set as p4 + 6
√
q̂t∆ + (q̂t∆)q, where q̂ = maxi qi).
complexity Expm Unif Eigen
Soft EM O(r(2S)4 + rL(2S)3) O(M̂S3 + rS3M2 + rS2LM2) O(rS5 + rLS4)
Hard EM O(r(2S)4 + rL(2S)3)
O(M̂S3 + min(rS2, V )SM2
+ min(rS2, V )LM2)
O(min(rS2, V )S3
+ min(rS2, V )LS2
1.1 Overview of main contributions
• Introduce CT-HMM with multi-dimensional (M-D) state structures for disease
progression modeling, which can statistically characterize the co-evolution mul-
tiple biomarkers, revealing the dynamic interactions in a more informed picture
of disease progression.
• Pair the M-D CT-HMM with novel state-based visualizations, facilitating com-
prehension of disease progression patterns.
• Present the first comprehensive framework for CT-HMM parameter learning
using EM, which both extends and unifies prior work on CTMC models.
• Develop several variants of EM algorithms for CT-HMM learning, including
(Soft,Hard) × (Expm,Unif,Eigen) combinations. The time complexity (see Ta-
ble 1) and accuracy of the developed methods are analyzed and compared ex-
perimentally by simulation and on real-world datasets. Our results show that
soft EM approach achieves higher accuracy and is more robust to noises than
hard EM. Expm in computing conditioned expectations works best in soft EM
while Unif can achieve the best efficiency in hard EM due to its decompos-
ability. Our work enables more efficient learning of CT-HMM than the prior
method which uses direct numerical optimization (see Table 2 for a complexity
comparison).
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Table 2: Time complexity comparison for CT-HMM learning using a direct numerical
optimization method (use Broyden-Fletcher-Goldfarb-Shanno (BFGS) [29]) to find
MLE and the proposed EM methods in this thesis. For BFGS, LV S2 represents the
evaluating of the likelihood function using Forward-Backward algorithm for each of L
parameters when calculate numerical differences. rS3 represents the precomputation
of matrix exponential for r distinct time intervals, which also needs to do for each
of L parameters when compute numerical difference. L2 costs is in updating the
approximated Hessian. In practice, V , the number of total visits in a dataset, can
be very large. Direct numerical optimization can be very time consuming due to the
LV S2 term.
complexity Direct numerical opt. End-state conditioned EM
CT-HMM
BFGS [29]:
O(LV S2 + LrS3 + L2)
Our thesis work
Soft(Expm): O(V S2 + r(2S)4 + rL(2S)3)
Hard(Unif): O(V S2 + M̂S3 + min(rS2, V )SM2
+ min(rS2, V )LM2)
• For CTMC an CT-HMM decoding tasks, derive new closed-forms for comput-
ing total time conditioned state sequence probability and path-and-total time-
conditioned expected state durations, which has better time complexity than
other alternative methods.
• Demonstrate applications of M-D CT-HMM on several disease contexts: Glau-
coma, Alzheimers disease, and Hypertension. Insights of the diseases are gained
by visualizing and analyzing the learned state transition tendencies. For Glau-
coma, the results on predicting future measurements outperforms the state-of-
the-art Bayesian joint linear regression method.
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CHAPTER II
RELATED WORK ON STATE-BASED DISEASE
PROGRESSION MODELING
In this chapter, we review several related work using state-based disease progression
models. These include: CT-HMM models which handle both a continuous-time state
transition process and noisy observation process (include a small CT-HMM in Sec.
2.1.1, a hybrid CT-HMM in Sec. 2.1.2, a large-scale CT-HMM modeled as a time-
inhomogeneous HMM in Sec. 2.1.3), other CT type models (include CTMC which
observes the state directly without noise handling [29], continuous-time latent Markov
model for phase-type duration modeling using 2-layers of CTMCs in Sec. 2.2.1,
and continuous-time Bayesian network (CTBN) in Sec. 2.2.2), and non CT models
(include discrete-time HMM in Sec. 2.3.1, Kalman filtering in Sec. 2.3.2, and Bayesian
probability model for event ordering in Sec. 2.3.3). We also briefly review other
widely-used non-state based longitudinal models in Biostatistics in Sec. 2.4.
In each section, we will briefly explain each referred disease model, and compare
the referenced model to our multi-dimensional CT-HMM , in terms of their ability to
model the same disease and dataset, and their possible pro and cons.
For state-based disease progression modeling, we believe that continuous-time
models are better than the discrete-time alternatives, such as DT HMM and Kalman
filter. Using these discrete-time methods to model continuous-time process, such as
disease evolution and clinical data, have both efficiency and accuracy issues. Note
that the time horizon for state changes in medical conditions can vary dramatically.
In early stages of disease a state change might not occur for years, but in an acute
phase they could occur very frequently. The intervals between clinical visits can also
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widely-vary depends on the disease conditions among patients. For states with very
short expected dwelling times, the discrete time step needs to be sufficiently small.
However, this might be inefficient for dealing with changes that occur once several
years. On the other hand, if the discretization is too coarse, many transitions could
be collapsed into a single one, obscuring the real dynamics in continuous-time. In
contrast, CT model performs inference over arbitrary timescales using a single matrix
exponential. We believe CT is a better choice than DT for modeling continuous-time
processes such as disease progression and clinical data.
2.1 Continuous-time hidden Markov model
2.1.1 Small CT-HMM
In [29], the paper reviews the prior works that used CTMC and CT-HMM for disease
progression modeling with panel data (observations at arbitrary times).1 The prior
applications include (1) screening for abdominal aortic aneurysms [26], for breast
cancer [13], and for cervical cancer [37] ; (2) problems following lung/heart trans-
plantation [27],[75],[38]; (3) staging for hepatic cancer [34], [6]; (4) complications for
diabetes [56]; (5) HIV infection and AIDS [72].
The commonly used disease models in the literature are shown in Fig. 3 for staged
progression (example in Fig. 5) and Fig. 4, the illness-death model (examples in
Fig. 6 ). The model in Fig. 3 consists of a series of successively more severe disease
states, and an absorbing state (dealth). The patient may advance into or recover from
adjacent disease states, or directly jump to the death state. The stages of disease may
be modelled as a continuous-time (hidden) Markov process, with a time-homogeneous
or time- inhomogeneous transition rate matrix.
This paper introduced an R package, msm, that allows a multi-state model to
be fitted to longitudinal data. Features of msm include the ability to learn transition
1In biostatistics, the term multi-state model is used more often to describe a process (Markov
or not) in which an individual moves through a series of states in continuous time.
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Figure 3: A conventional disease progression model which has a linear state chain.
At each state, multi-dimensional features may be used, but the detailed temporal
relationship among these features can not be captured in this linear chain model
(from [29], used without permission).
Figure 4: Healthy-illness-death model (from [29], used without permission).
Figure 5: A three-state model for breast cancer progression. State 1: no detectable
breast cancer; state 2: preclinical cancer, detectable by screening (asymptomatic);
state 3: clinical breast cancer (symptomatic) (from [88], used without permission).
Figure 6: A three-state hidden Markov model for modeling progressing from liver
cirrhosis to hepatocellular carcinoma (HCC) (from [6], used without permission).
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rates in CTMC and CT-HMM with/without covariates, and the ability to model
data with a variety of observation schemes, such as censored states. However, in
this package, direct numerical optimization methods, such as BFGS, are adopted for
maximum likelihood estimation of model parameters. As we pointed out in Chapter
1, the direct numerical optimization method does not scale well with large state space.
Our M-D disease progression modeling generalizes the existing 1-D model, which
can capture the dynamics among multiple factors. In addition, our proposed EM
learning method can efficiently learn the parameters for a larger scale models of
hundreds of states.
2.1.2 Hybrid CT-HMM
In [90], the paper proposes a probabilistic disease progression model which has three
layers (see Fig. 7): the top layer is a CT-HMM for modeling the hidden progression
stages, the middle layer is a set of comorbidities2 whose onsets trigger the state tran-
sition of the top layer, and the bottom layer are the observed clinical findings, which
are activated by the hidden comorbidities. A bipartite noisy-or discrete-time Bayesian
Network is used to model the relationship between the middle comorbidity layer and
the bottom observed clinical finding layer (see Fig. 8). The model is demonstrated
on Chronic Obstructive Pulmonary Disease (COPD) patient cohort with Electronic
Health Record (EHR) data, and some interesting clinical insights are gained.
Aiming to learn a general-purpose model for any chronic disease based on a general
input data type, such as EHR, the authors do not assume prior knowledge of either the
ground truth progression stages or the key indicators that signify the stage transitions.
Since the onset of a new comorbidity often signifies the exacerbation of the target
disease, the authors use the onset pattern of multiple comorbidities to collectively
2A comorbidity is a disease or syndrome that co-occurs with the target disease. For example,
hypertension is a common comorbidity of diabetes and osteoporosis is a common comorbidity of
COPD [90].
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Figure 7: A disease model of three layers of variables: S are hidden progression state
variables, X are hidden comorbidity variables, and O are observed clinical findings
(from [90], used without permission).
Figure 8: The noisy-or Bayesian network. The clinical findings can be activated by
a hidden comorbidity or by the always-on hidden cause (the leak term). The starred
finding O1 is an anchor, which means it can only be activated by a specific comorbidity
(X1 in this example). (from [90], used without permission).
drive the state transitions of the target disease. Also, it is assumed that once a
comorbidity is turned on, it can not be turned off in the future.
An EM learning algorithm with Gibbs sampling to jointly model the distribution of
hidden variables and model parameters is used for parameter estimation. For COPD
disease, 6 progression states and 10 comorbidities are used, where each comorbidity
is guided with a set of predefined anchor observations to improve interpretability.
The results are in Fig. 9 and Fig. 10. In Fig. 9, one can see that the prevalence of
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some comorbidities raise rapidly with the state transitions, while some comorbidities
remain more stable. In Fig. 10, the inference result of two patients, one has a stable
and another has a progressive trajectory are shown, which reveal the heterogeneity
of different progression patterns.
Figure 9: The progression state over time versus the comorbidity prevalence averaged
over 10000 generated virtual patients (from [90], used without permission).
(a) A stable trajectory (b) a progressive trajectory
Figure 10: Inference of the progression trajectory and comorbidity onset of two pa-
tients. Inferenced stages and comorbidity onsets are shown in the top and the gray
bar respectively. The stars denote the observed clinical findings (From [90], used
without permission).
When compare this comorbidity-driven progression model to our MD CT-HMM
model, our MD model is more suitable to directly model the interactions of the known
key disease indicators. The other clinical observations as well as treatment effects can
be incorporated as covariates, whose weights are to be learned from the training set.
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The learned weights reveal whether a covariate is significant in influencing the state
transition rates. And by using covariate model, each patient can have individualized
state transition matrix at each visit. In addition, these covariates can be binary or
continuous values, and they can be on or off at any visit time.
In contrast, the comorbidity model uses the onset patterns of hidden comorbidities
to define the progression of the target disease, which complements existing standards
that directly use the key indicators to define stages, in offering a comprehensive
characterization of the patient’s conditions. One restrictive assumption is that the
comorbidity can not be turned off once it is on. We think that the new progression
definition based on hidden comorbidities are novel. However, some hidden causes
are not specific to the target diseases, but are common to many diseases, such as
anxiety in psychological group and obesity, or it may be more related to aging. We
think that some discriminative analysis and feature selection steps are required for
this comorbidity model.
2.1.3 Large-scale CT-HMM with state transition constraints
In [42], the authors points out that the lack of efficient parameter estimation algo-
rithm for CT-HMM has limited its applications to very small models. They thus
develop a Baum-Welch like EM algorithm for large-scale CT-HMM, with restrictive
assumptions that state transitions take place exactly and only at observation times.
This assumption also implies that two states which has a path should also have an
instantaneous link. We find that these assumptions may be too restrictive and not
realistic for real-world applications.
The method is applied to analyze the temporal interactions among 74 psychiatric
diseases, from around 375000 patients traced over 30 years with a total of around
7,000,000 clinical visits. The paper presents the visualization of the learned disease
interaction (Fig. 11 and 12) so that possible causal interactions may be identified.
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The prediction of future disorders given a current disease is also shown (see Fig. 13).
It shows that the predicted future diseases (left) using the model are in accordance
with the real trajectories (right) directly calculated from the data.
To our knowledge, this paper is the first application of CT-HMM with a large
number of states, but an approximate parameter estimation algorithm with restrictive
state transition assumption is used. Our new CT-HMM learning methods do not have
these assumptions and can be applied to this application as well.
Figure 11: Visualization of the strongest interactions of the transition intensity qij
(from [42], used without permission).
Figure 12: Visualization of the strongest interaction from the transition probability
pij = qij/qi (from [42], used without permission).
Figure 13: Prediction of future disorders (y axis) over time (x axis) when given a
fixed current disease state (A81) (from [42], used without permission).
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2.2 Other continuous-time models
2.2.1 Continuous-time latent Markov Model
A latent CTMC model is proposed in [86] for for more flexible, duration-dependent
disease state sojourn time modeling than conventional CTMC, where sojourn time
distribution is exponential and can be unrealistic for real applications. This model
assumes that the disease process is characterized by an underlying latent CTMC,
with multiple latent states mapping to each observed disease state (see Fig. 14). This
model allows flexible sojourn time modeling while retain analytic tractability of data
likelihood due to the CTMC framework. In contrast, the semi-Markov models that
permit generic sojourn time distribution but yield intractable likelihood particularly
if the model has reversible transitions.
In more detail, a latent CTMC structure implies phase-type (PH) distributions of
sojourn times in each disease state. PH distributions are attractive in their ability
to approximate generic distribution with positive support, and PH functionals are
Figure 14: (a) An example of latent trajectory X(tl), disease trajectory W (tl), and
observed data O(tl) at irregularly observed times for model structure in subfigure c,
assuming possible observed error. (b) A two-state survival model assuming disease
states = 1, 2 and latent states = 11, 12, 2, where state 2 is absorbing. (c) A two-state
reversible model with disease states = 1=Healthy, 2=Diseased, and latent states
= 11, 12, 21, 22. (from [41], used without permission).
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expressible with matrix exponentials [41][86]. One disadvantage of PH is that model
parameters may not be identifiable [41]. The latent CTMC models for disease pro-
cesses inherit these advantages and disadvantages of PH distributions. In practice,
models with few latent states are more likely to result in identifiable parameters.
The original inventor of latent CTMC [86] suggests using standard numerical
optimization methods for obtaining MLE model parameters. However, this method
is slow and exhibit poor convergence properties as noted in [41]. [41] proposes a new
EM algorithm for latent CTMC that combines recent computational development
derived for PH models [4] and discretely-observed CTMCs [7], which results in better
time efficiency in learning.
Simulation study is conducted [41] for latent CTMCs using simple two-state sur-
vival and healthy-illness model, where each disease state has an underlying CTMC
of 1 or 2 states. The interpretive power of latent CTMC models for describing dis-
ease process for a bronchiolitis obliterans syndrome (BOS) dataset of lung transplant
patients. Overall, the results suggest mixed performance of latent CTMC estimates.
The latent CTMC though flexible, are parametric and is subject to model misspeci-
fication.
As very small disease models are demonstrated in [41], we think that further
investigation is needed to test the feasibility of latent CTMC to applications of a
larger number of disease states with duration modeling.
2.2.2 Continuous-time Bayesian network
In [20], a continuous-time Bayesian network (CTBN) is utilized to diagnose cardio-
genic heart failure and anticipate its likely evolution. This paper describes the first
clinical application of CTBN, which overcomes the regular-sampling assumptions of
dynamic Bayesian network (DBN). The model structure for diagnosing heart failure
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and complications is shown in Fig. 15, which consists of both unobservable physi-
ological variables and clinically observable events. By conducting inference on this
model, one can predict the occurrence of complications (such as myocardial infarca-
tion, shock) and the persistence in time based on the gathered evidence. The inference
results are shown to be consistent with the current medical understanding.
The key parameters of the CTBN model, i.e., the conditional intensity matrix
(CIM), are elicited on the basis of the medical expertise [20]. The authors provide a
procedure to specify CIM by first entering the conditional probability table (CPT)
that within a short-enough time interval, to represent the influence of the parent
nodes on each node as the corresponding CIMs would do in continuous time. Please
see [20] for more detail on parameter specification based on expert knowledge. In
the future work, the authors would like to directly learn the CIMs from clinical data,
which is challenging and is still an active research problem.
Figure 15: CTBN model for diagnosing cardiogenic heart failure (from [20], used
without permission).
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2.3 Non continuous-time models
2.3.1 Discrete-time HMM
In [91], the paper uses DT-HMM to model brain aging using 4D (3D + time) brain
MRI images. A 5-state left-to-right DT-HMM, as shown in Fig. 16 is used to capture
the changes of aging-related brain regions over time. In the results, the authors com-
pared the patient age distribution at each state and the number of state transitions
for two patient groups based on their cognition scores. One group is cognitive decline
(CD), and the other is non-cognitive decline (NCD), classified based on the change
slope of cognition scores. The main findings are as follows. For CD group, the mean
age between two successive states are shorter (Fig. 17), and the frequency of state
transitions are higher than the NCD group (Fig. 18).
Figure 16: A 5-state left-to-right discrete-time HMM for modeling brain aging (from
[91], used without permission).
Figure 17: Average age at each state for relatively healthy (Non-Cognition Decline)
and progressive group (Cognition Decline) (from [91], used without permission).
We believe that our multi-dimensional CT-HMM progression model can be uti-
lized in this application to analyze and visualize the interaction between structural
degeneration (physical brain changes) and functional deterioration (cognition decline)
directly. In more detail, the same left-to-right model can be trained first using the
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Figure 18: Histogram of number of state transitions from each state in NCD (non
cognition decline) and CD (cognition decline) group (from [91], used without permis-
sion).
structural features, and the data emission model for each state is learned. Then the
2D state space is defined by bands of cognition scores and the learned structural
states. This can be an interesting future work.
2.3.2 Kalman filter
In [73], Kalman filter is used to estimate the true value of biomarkers associated with
Open-Angle Glaucoma (OAG) from noisy observations and the filtered values are
then fed into a logistic regression function to classify patients as progressors or non-
progressors. It is shown that using Kalman filter first resulted in data input which
improved the classification accuracy compared to the model fed by raw measurements.
We compare the main differences between Kalman filter and CT-HMM model for
data denoising. The state space in Kalman filter is continuous while that for HMM
is discrete. One strong assumptions in Kalmain filter is that all hidden and observed
variables have Gaussian distribution, while in HMM there is no specific constraints
in data distribution. In addition, the basic Kalman filter is a linear system that has
a global transformation matrix not varies with the current state, while in HMM the
transition behavior depends on the current states. Regarding to the decoding step,
Kalman filter is an on-line sequential processing method, while HMM uses Viterbi
decoding to find the best hidden state sequence in a batch mode.
In modeling disease progression where non-linear transitions are expected over
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time and among markers, we believe that state-dependent transition behavior are
required to capture the state-varying progressing behavior. Thus, abstraction of
disease states to a finite set may be needed. Furthermore, in settings where we are
given a set of measurements from past visits, it is better to find the optimal hidden
state sequence considering all these measurements, rather than using the sequential,
on-line decoding method. Furthermore, we would like to use a continuous-time model
where the observations can be irregularly spaced in time, while the basic Kalman
filter requires regular discrete-time observations. Due to these reasons, we believe
that CT-HMM is a more suitable choice in modeling and decoding the non-linear
state-dependent transition behavior.
2.3.3 Bayesian probability model for event ordering
In [18], the paper introduces a new characterization of disease progression, which
describes the disease as a series of events (we illustrate this in Fig. 19), and each
event represents a significant change in some aspect. The aim is to learn the most
common event ordering from measurements over a patient cohort. The applications
to familial Alzheimer’s and Huntington’s diseases are demonstrated. The found event
ordering model can be used to do patient staging. Also, more understanding about
different but similar neurodegenerative diseases can be gained, by comparing their
event orders respectively.
In the formulation, [18] treats longitudinal data as cross-sectional data, which
means that visits from the same patients are treated as they are irrelevant. The data
likelihood for a given event ordering S is formulated as follows. If cross-sectional
data j is at position k in the event-based progression model, events Es(1), ..., Es(k) has
occurred, while events Es(k+1), ..., Es(N) has not, the likelihood for that patient’ data





where Xj = [x1j, ..., xNj, ] represents the j’s cross-sectional data for events 1, ..., N .
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Integrating out the hidden position k, one obtains: p(Xj|S) =
∑N
k=0 p(k)p(Xj|S, k).
And for all cross-sectional data, we have p(X|S) =
∏J
j=1 p(Xj|S). Finally, Bayesian
theorem is used to obtain posterior distribution for the ordering S: p(S|X) = p(S)P (X|S)/P (X).
Then MCMC sampling is used to sample from p(S|X) to derive the most common
ordering and the ordering variance (see Fig. 20).
Figure 19: Disease progression as a series of events, each comprising a significant
change in patient state.
Figure 20: MCMC sampling for the event order S (from [18], used without permis-
sion).
Figure 21: The found most common event ordering for Alzheimer’s disease (from [18],
used without permission).
The found most common event ordering is shown in Fig. 21 and the position
variation derived from the MCMC samples is shown in Fig. 22(a). The learned event
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model can be used to stage a cross-sectional data by computing the most probable
current event location. The staging results for follow-up data for all patients are
illustrated in Fig.22(b). The results provide new detail in the progression pattern of
these diseases, while confirming known features, and give insight into the variability
of progression over the patient cohort.
This event-based progression model has several merits but its current formulation
has some limitations. First, it treats longitudinal data as cross-sectional data, and
thus it does not use the full information from the longitudinal data in event posi-
tioning and measurement denoising. Second, the formulation ignores the duration
information between visits, and thus no duration information between events can be
statistically characterized.
We think that CT-HMM can also be utilized to deriving the most probable event
ordering while overcoming the above two limitations. One idea is as follows. We can
first using clustering techniques to find disease states from the cross-sectional data,
and then model the temporal interactions among these states. As one can easily
derive the probability of event occurrence in each state, the overall event ordering
can be inferred from the learned model.
(a) (b)
Figure 22: (a)The distribution of positions for each event from MCMC samples. (b)
The most probable event location for each follow-up visit for each patient. (From
[18], used without permission).
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2.4 Other multivariate longitudinal models in Biostatistics
Here, we will briefly discuss the univariate longitudinal models, and their extensions
to multivariate longitudinal models developed in Biostatistics fields [5].
For univariate longitudinal analysis where there is one response variable and pos-
sibly many explanatory variables, fixed effect model, random effect model, and mixed
effect model are well-established and widely used linear models in biostatistics. A
fixed effect model represents the observed quantities in terms of explanatory vari-
ables that are treated as non-random. In contrast, random effects models and mixed
effects models have some explanatory variables treated as if they arise from random
causes [93]. In biostatistics, ”fixed” and ”random” effects are often used to refer
to the population-average and subject-specific effects where the former is associated
with fixed parameters while the latter is treated as random variables. In addition to
the above three linear models, the generalized linear model (GLM) generalizes linear
regression by allowing the linear model to be related to the response variable via a
link function, such as exponential.
Multivariate longitudinal data means that there are repeated observations of mul-
tiple response variables. Special treatments are required to analyze this data as they
are correlated over time and multiple responses measured at the same time are also
correlated. [5] reviews three approaches for analyzing this kind of data. The first
is to transform the multiple outcomes to a single summary variable and then use
univariate longitudinal model on the summary outcome, which is conceptually the
simplest, but the summary variable can be hard to interpret. The second method es-
timates regression coefficients without explicitly modeling the underlying covariance
structure of the data. The third approach combines all the responses into a single
joint multivariate model and is the most complicated.
Comparing the prior work to our MD CT-HMM, we find that many existing lon-
gitudinal methods in biostatistics for non-linear modeling require synchronous time
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sequences, i.e., there are explicit or implicit correspondence between the timestamps
of different patients. For example, tracking of a set of patients following the a sur-
gical operation. For this time synchronous setting, spline model [5] can be useful
for modeling nonlinear dynamics by putting a set of knot points on specified times.
However, the longitudinal data for tracking chronic disease often have no time align-
ments among patients. This time synchronization is not required in our CT-HMM
formulations, where the longitudinal data can start and begin at any state of the
progression path. Furthermore, our MD CT-HMM explicitly models the state depen-
dent transition behavior while conventional longitudinal model, such as mixed effect
model, seeks a global mean path (average intercept and slope) and the variance of
the heterogeneity (the random effect) which is much more compact but also have
limited expressive power. In sum, our MD CT-HMM has benefits in modeling the
underlying state-dependent evolution behavior and can naturally handle sequences
without aligned reference times.
2.5 Conclusion
We reviewed several related state-based disease progression models and compare those
models to our M-D CT-HMM in similar applications. CT-HMM models that can han-
dle both continuous-time state transition process and noisy observation process are
in principle better suited models for disease progression modeling with noisy clinical
data than other continuous-time models without a separate observation process and
other discrete-time models.
Our M-D CT-HMM which can analyze the temporal interactions of several disease
markers/aspects with covariate modeling, is the extension of the conventional 1-D
HMM-based disease progression models, which gives a more informed global view
of the disease evolution. The novel parameter learning algorithms for CT-HMM
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proposed in this dissertation also enable the applications of CT-HMM with large-
state space, but without the restrictive assumptions on state transition timing, which
forced in prior work. We also describe that CT-HMM can be utilized to model event
transitions for Alzheimer’s disease and both the event ordering and timing information
can be inferenced, while the referred prior work ignores the time but only models the
relative ordering.
A prior work using a hybrid CT-HMM for comorbidity-based disease staging mod-
eling is discussed. This model does not directly use the key markers for defining
disease progression, but is based on the onset patterns of hidden comorbidities infer-
enced from clinical observations. In contrast, our M-D CT-HMM defines the disease
progression directly using the key markers while other clinical observations can be
incorporated as covariates to construct individual-level transition rate matrix. We
think that both models are valuable in defining disease progression from different
perspective, which complement each other.
We also discuss a prior work that uses a double-layer CTMC for phase-type du-
ration modeling in CTMC applications. This model may provide better duration
modeling for CTMC models than the basic exponential distribution. However, fur-
ther investigations are needed for assessing the use of this model in large-scaled state
space and in CT-HMM settings.
We also briefly review several wide-used longitudinal models in Biostatistics. We
find that our M-D CT-MM model has benefits of modeling non-linear progression
from time-asynchronous records of patient data using composite disease states, which
can flexibly capture multivariate interaction, while other non-linear models, such as
spline, generally needs time alignments of longitudinal records.
Overall, our M-D CT-HMM introduces a novel way to analyze the temporal in-
teractions of different disease evolution aspects (structural, functional, biochemical,
etc.), and covariates can also be incorporated to learn and construct individualized
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transition rates. Our MD CT-HMM is complementary to many existing disease mod-




EFFICIENT CT-HMM PARAMETER LEARNING USING
END-STATE CONDITIONED EXPECTATION EM
A Continuous-Time HMM (CT-HMM) is an HMM in which the transitions between
hidden states and the observations can both occur at arbitrary continuous times
[16]. It is thus more suitable for modeling continuously evolving process such as
disease progression, and irregularly-arrived data such as clinical measurements than
conventional discrete-time HMM in which both the state transitions and observational
data occur at regular time intervals. The comparison of the underlying state transition
process and observation process between discrete-time(DT) HMM and CT-HMM is
illustrated in Fig. 23.
Figure 23: Comparison of discrete-time HMM and continuous-time HMM. (a) In con-
ventional HMM, state transitions and observations happen at regular time intervals
∆t. States are allowed to self-transition. (b) In continuous-time HMM, state transi-
tions occur in unknown continuous-time (t′1, t
′
2, ...) (always transition to other states),
and observations also arrive at arbitrary times (t1, t2, ...).
Unfortunately the additional modeling flexibility provided by the CT-HMM comes
at the cost of a more complex inference procedure than DT-HMM. In CT-HMM, not
only are the hidden states unobserved, but the transition times at which the hidden
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states are changing are also unobserved. It is possible for multiple unobserved hidden
state transitions to occur between two successive observations. An early parameter
learning algorithm circumvent these challenges of explicit hidden path decoding by
directly maximizing the data likelihood [29] using numerical optimization, but this
method is limited to very small model structures. The lack of efficient learning al-
gorithms has limited CT-HMM to applications of small models [29] or for large-scale
models require unrealistic assumptions on state transition timing [42, 52]. There is a
need for learning methods for CT-HMM which can scale to large state space [42].
Figure 24: The graph shows a CTMC process under incomplete observations. Sim-
ilar to CT-HMM, in a CTMC both the state transitions and observations occur at
arbitrary continuous time. However, in a CTMC the observation data (yv) are the
hidden states at the observed moment (yv = s(tv)).
With the challenges of learning CT-HMM, one may resort to simply discretize
the time horizon and just use discrete-time HMM. However, the time horizon for
state changes in medical conditions can vary dramatically. In early stages of disease
a state change might not occur for years, but in an acute phase they could occur
very frequently. For states with very short expected dwelling times, the discrete time
step needs to be sufficiently small. However, this might be inefficient for dealing
with changes that occur once several years. On the other hand, if the discretization
is too coarse, many transitions could be collapsed into a single one, obscuring the
real dynamics in continuous-time. In contrast, CT model performs inference over
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arbitrary timescales using a single matrix exponential. We believe CT is a better
choice than DT for modeling continuous-time processes such as disease progression
and clinical data.
To tackle the challenges of CT-HMM learning, if we consider a simpler case where
the observation process observes the hidden states directly without noise but still
at arbitrary times, then CT-HMM is equivalent to a continuous-time Markov chain
(CTMC) model under incomplete observations (only knows the states at discrete
observation times). An illustration of CTMC state transition process and incomplete
observation process is shown in Fig. 24. EM algorithms for this CTMC setting to
find maximum likelihood solution were developed recently [7, 64, 25]. They work
by computing expected state durations and transition counts conditioned on each
pair of successive state observations. In [64], efficient closed-form evaluations are
obtained when the rate matrix can be diagonalized through an eigendecomposition
(abbreviated as Eigen). Such an approach has been extended to CT-HMM [90].
However, the rate matrix is frequently not diagonalizable during learning, and this
approach often fails in real data [64].
More recently, [25] demonstrated that the necessary conditional expectations can
also be evaluated using two alternative approaches. One approach (abbreviated as
Expm) uses a double-sized auxiliary matrix with respect to the rate matrix in com-
puting the matrix exponential, while the other (abbreviated as Unif ) utilizes the
uniformization theory. For CTMC applications, it has been shown that Expm ap-
pears to be the most accurate, but is the most expensive [83]. Unfortunately, none of
these methods have been explored or developed for CT-HMM, which has the ability
to correctly account for measurement noise and offers more flexibility to clinicians in
describing the relationship between measurements and disease states.
We present the first comprehensive framework for parameter learning in CT-HMM
models of disease progression, which both extends and unifies prior work on CTMC
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models. Based on the finite number of observations, our framework discretizes the
estimation of posterior hidden state probabilities at observation times into a time-
inhomogeneous HMM, and then incorporates two approaches to estimating the hidden
state distributions. In the “hard” approach, the distribution over hidden states is ap-
proximated by the single most likely (Viterbi) decoding, which results in significant
computational savings. The “soft” approach, in contrast, maintains the full distribu-
tion over the hidden states, gaining accuracy at the cost of increased computations.
The benefits and drawbacks of these two approaches (Soft and Hard) combined with
the three different computational approaches for evaluating the conditional expecta-
tions (Expm, Unif, Eigen) are analyzed and validated experimentally.
Our learning algorithms for CT-HMM are evaluated on both synthetic data and
real-world disease datasets. For the simulation, we assess the learning accuracy of
our methods with respect to different observation intervals, observation counts, and
varying noise levels. We find that soft methods are more robust than hard methods
especially when the noise levels are high. The running time of our EM algorithms
are also compared under different synthetic or real data. We find that Soft(Expm)
method is the most time efficient under soft EM, while Hard(Unif) method can be the
most economic in hard EM due to its decomposibility in evaluating only the required
end-states and better generality than Eigen method.
For the two real datasets from glaucoma and Alzheimer’s disease, we demonstrate
applications include visualizations of the progression model and predictions of future
progression. Our prediction results outperform the state-of-the-art method [62] for
glaucoma prediction, which shows the practical value of CT-HMM for longitudinal
disease prognosis and management.
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3.1 Basic formulations of CTMC and CT-HMM
A continuous-time Markov chain (CTMC) is defined by a finite and discrete state
space S, a state transition rate matrix Q, and an initial state probability distribution
π. The elements qij in Q are non-negative and describe the rate (instantaneous risk)
the process transitions from state i to j, for i 6= j and qii are specified such that each
row of Q sums to zero (the holding time parameter qi =
∑
j 6=i qij and qii = −qi) [16].
In the most general form, Q can be time-inhomogeneous, and one can express qij as:
qij(t, z(t)) = lim
δt≈0
p(s(t+ δt) = j|s(t) = i)
δt
where s(t) represents the state at time t, and z(t) represents a set of individual-
level constant or time-varying covariates (explanatory variables), such as age, and
treatment history. In a time-homogeneous process, in which the qij are independent
of t, the sojourn time (a single period of occupancy) in each state i is exponentially-
distributed with the holding time parameter qi as f(t) = qie
−qit, which has mean
1/qi. The probability that an individual in state i moves next to state j is qij/qi, for
i 6= j. The Markov assumption states that the future of the process depends only on
the current state and not on the history. For a thorough review of continuous-time
Markov chain (CTMC) theory, please reference Cox and Miller [16].
The continuous-time Markov model for panel-observed data (observations arrived
at arbitrary times) was first described by Kalbfleisch and Lawless [32] and Kay [33].
In the most general form, the transition probability pij(t0, t) represents that given
the state at time instant t0 is i, the probability of being in state j at time instant
t. The transition probability matrix P (t0, t) is calculated in terms of Q(t) using the
Kolmogorov differential equations [16] as follows:
dP (t0, t)
dt
= P (t0, t)Q(t).
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The general solution to the Kolmogorov differential equations is:










Q(t1)Q(t2) · · ·Q(tk)dt1dt2 · · · dtk
where k represents the number of possible state jumps which ranges from 0 to ∞,
and t1 · · · tk represents the times of these jumps.
If the transition intensity matrix Q is constant over the time interval (t0, t), as in
a time-homogeneous process, then P (t0, t) can be expressed as P (τ) where τ = t− t0
represent the time interval. In this case, the Kolmogorov equations are solved by the
matrix exponential of Q scaled by the time interval τ :
P (τ) = eτQ.
The matrix exponential is defined by the same power series eX = 1+X2/2!+X3/3!+...
as the scalar exponential, except that each term Xk is defined by matrix product,
not element-wise scalar product. The matrix exponential can be solved by Pade
approximation [23].
We now describe CT-HMM. In contrast to CTMC, where the states are directly
observed, in CT-HMM, none of the state is directly observed, but observational data
o are generated conditioned on the hidden states s from a data emission model p(o|s)
[16] [29]. This emission model is used to capture the fact that the real world data
is a noisy or transformed version of the true state. Furthermore, the observations
(o0, o1, . . . , oV ) are typically collected in only at discrete and irregular time points
(t0, t1, . . . , tV ). In other words, there are two levels of hidden information in CT-
HMM. First, at the observation times, the true state of the Markov chain is not
observed. Second, the Markov chain between two consecutive observations is hidden,
and the Markov chain may have visited other states before it reaches the state at
the observation time. While CT-HMM is in principle a better model for real world
data, the two levels of complication makes the parameters in CT-HMM even more
challenging to estimate.
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3.2 Prior work: Maximum Likelihood Estimation in CTMC
When a realization of the CTMC is fully observed, meaning that one can observe
every state transition time, (t′0, t
′
1, . . . , t
′
V ′), and the corresponding state Y = {y0 =
s(t′0), ..., yV ′ = s(t
′
V ′)}, where s(t) denotes the state at time t, the complete likelihood



















where τv′ = t
′
v′+1 − t′v′ is the time interval between the two successive observations,
nij is the total number of transitions from state i to j, and τi is the total amount









However, a realization of the CTMC is typically observed only at discrete and
irregular time points (t0, t1, ..., tV ) with the corresponding state sequence Y = {y0 =
s(t0), ..., yV = s(tV )}. The process between the two consecutive observations is hidden,
and the Markov chain may have visited other states before it reaches the observed
state. Thus both the transition counts between any two states i and j, denoted as
nij, and the total duration in a state i, denoted as τi, are unknown. In Fig. 25
the comparison of the state transition and observation process between fully and
partially-observed CTMCs is illustrated.
In order to express the likelihood of these incomplete observations, one needs to
use the state transition probability matrix, P (t) = eQt, where Pij(t), the entry (i, j)
in P (t), is the probability that the process is in state j after time t given that it is
in state i at time 0. This quantity takes into account all possible intermediate states
and state durations visited between i and j but not observed. Then the likelihood of
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Figure 25: Comparison of the state transition and observation process between (a)


















where τ∆, ∆ = 1, ..., r, represents r unique values among all time intervals τv from
the data, I(yv = i, yv+1 = j) is an indicator function that is 1 if the condition is true,
otherwise it is 0, and C(τ = τ∆, yv = i, yv+1 = j) is the total counts from every two
successive visits when the condition is true. Note that there is no known analytical
maximizer of L with respect to Q.
An EM algorithm is designed recently to tackle this challenge [64], where the





{log(qij)E[nij|Y, Q̂0]− qiE[τi|Y, Q̂0]},
where Q̂0 is the current estimate for Q, and E[nij|Y, Q̂0] and E[τi|Y, Q̂0] are the
expected state transition count and duration given the observation Y and the current
transition rate matrix Q̂0, respectively. This expected log-likelihood is derived from
the complete data likelihood (CL) for algebraical simplicity for derivation without
loss of generality [7][64].
Once the two kinds of statistics E[nij|Y, Q̂0] and E[τi|Y, Q̂0] are computed, the









Now the main computational challenge is to evaluate E[nij|Y, Q̂0] and E[τi|Y, Q̂0].
By exploiting the properties of the Markov process, the expectations can be decom-
posed as [7]:
E[nij |Y, Q̂0] =
V−1∑
v=0












C(τ = τ∆, yv = k, yv+1 = l)E[nij |yv = k, yv+1 = l, τv = τ∆, Q̂0] (8)
where I(yv = k, yv+1 = l) = 1 if s(tv) = k and s(tv+1) = l, otherwise it is 0, and
C(τ = τ∆, yv = k, yv+1 = l) is the total counts from every two successive visits when
the condition is true. The derivation for E[τi|Y, Q̂0] can be done similarly. Thus, the
computation now boils down to computing the end-state conditioned expectations
E[nij|yv = k, yv+1 = l, Q̂0] and E[τi|yv = k, yv+1 = l, Q̂0], for all required k, l, i, j ∈ S.
A key result enabling efficient computation of end-state conditioned statistics of
CTMC is the derivation of their integral form in recent literature [24]:


























Q(t−x))j,l dx. It is then important to compute τ
i,i
k,l(t) and
τ i,jk,l (t) efficiently.
[64] observed that the calculation of τ i,jk,l (t) can be done in closed-form if Q is
diagonalizable and one can act eigendecomposition on Q (denoted hereafter as the
Eigen method) [24, 64, 65, 25]. Consider the eigendecomposition of Q = UDU−1,
where the matrix U consists of all eigenvectors to the corresponding eigenvalues of
Q in the diagonal matrix D = diag(λ1, ..., λn). Then we have e
Qt = UeDtU−1 and









the symmetric matrix Ψ(t) = [Ψpq(t)]p,q∈S is defined as: Ψpq(t) = te
tλp if λp = λq,
and Ψpq(t) =
etλp−etλq
λp−λq if λp 6= λq. However, not all Q matrices during learning are
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diagonalizable. We will then discuss alternatives and more general methods that
recently discovered to compute τ i,jk,l (t) in Section ??.
3.2.1 Evaluation of end-state conditioned expected statistics
Besides Eigen method, we now describe two alternative methods, one called ma-
trix exponential, and the other called uniformization method from [25], to evaluate




Q(t−x))j,ldx, in order to compute the sufficient statistics
E[τi|s(0) = k, s(t) = l] =
τ i,ik,l(t)
Pk,l(t)




to update Q parameters during learning.
Matrix Exponential for evaluating the integral (abbreviated as Expm):





can be done using the theory developed in Van Loan [89]. Consider the problem of
evaluating the integral of the form
∫ t
0
eQxBeQ(t−x)dx , where B is a matrix of the same
dimension as Q, [89] has shown that the integral result is the upper-right corner of






, and n is the dimension of matrix Q.
Now, the key observation from [25] is by setting up B = U(i, j), where U is the
matrix with a 1 in the (i, j)th entry and 0 elsewhere, and then the integral results in
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. So one can do matrix exponential on A and retrieve the
resulting top-right corner to get the desired τ i,jk,l (t) values.
Uniformization method (abbreviated as Unif ) [25]:
The uniformization theory shows how CTMC and DTMC is equivalence subor-
dinated to a Poisson process (see [70]) and gives an alternative description of the
CTMC process. It was used as an alternative method for computing matrix expo-




I is the identify matrix. Then, we have











, where Pois(m; q̂it) is the probability of m occurrences from a Poisson distribution
with mean q̂it. In practice, a truncation point of the infinite sum has to determined.
One benefits of using this method is that when one has same Q, but varying t to be
evaluated, the R power series can be precomputed and reused, and thus can be very
efficient in this scenario.
Then the necessary expectations can be expressed by directly inserting the eQt
definition into the integral [25]:


















The main difficulty in using Unif in practice is to determine a truncation point of
the infinite sum. For large values of q̂t, we have Pois(q̂t) ≈ N(q̂t, q̂t), where N(µ, σ2)
is the normal distribution and one can then bound the truncation error from the
tail of Poisson by using cumulative normal distribution [83]. A truncation point
41
at M = p4 + 6
√
q̂t + (q̂t)q is suggested in [83] to have error bound of 10−8 when
approximate eQt, which we will adopt in our unif-based learning algorithm.
3.3 Prior work: parameter learning for CT-HMM
The commonly-used existing methods to estimate parameters for CT-HMM are re-
viewed below. For Maximum Likelihood Estimation (MLE) based methods, numerical
optimization, such as the BroydenFletcherGoldfarbShanno (BFGS) algorithm, is gen-
erally adopted to directly optimize the data likelihood function L below [29] (used in










which considers all possible hidden state sequences Y at observation times, and
P (τv) := e
Q̂τv , τv = tv+1 − tv (For simplicity, likelihood assumes one longitudinal
data is shown.The data likelihood for all individuals is computed by multiplying the
individual likelihood together). L can be evaluated using Forward-Backward algo-
rithm as in discrete-time HMM case.
Recently, the EM algorithm developed for CTMC with eigen-decomposition method
to evaluate the end-state conditioned expectations (as discussed in Sec. 3.2) has been
applied to learn the rate matrix in a hybrid CT-HMM system [90]. However, the
eigen method can often fail during learning and is not a general method. Another
EM method to find MLE developed in [42] assumes that the state transition can only
occurs exactly at the observation times, and thus embeds a discrete-time Markov
chain into the continuous-time setting. However, this assumption is too restrictive to
capture the real system dynamics and can introduce artifacts. There is also Bayesian
method with prior using Markov Chain Monte Carlo sampling [14] to estimate the
probability distribution of parameters.
In our experiences these existing methods (direct numerical optimization and
MCMC sampling) which do not exploit much of the problem properties, do not scale
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up well with the state space (the time complexity will be discussed below). There is
a need for efficient and genearl parameter learning method for large-scale CT-HMM
without restrictive assumptions on state transitions.
3.4 Maximum Likelihood Estimation for CT-HMM
In this section, we describe our framework to do maximum likelihood estimation for
CT-HMM, by extending and unifying the work from CTMC. In contrast to CTMC,
where the states are directly observed, in CT-HMM, none of the state is directly
observed, but observational data o are generated conditioned on the hidden states s
from a data emission model p(o|s). This emission model is used to capture the fact
the real world data is a noisy or transformed version of the true state. Furthermore,
the observations (o0, o1, . . . , oV ) are typically collected in only at discrete and irregular
time points (t0, t1, . . . , tV ).
There are two levels of hidden information in CT-HMM. First, at the observation
times, the true state of the Markov chain are also not observed. Second, the Markov
chain between two consecutive observations is also hidden, which can have zero or
many state jumps. While CT-HMM is a better model for real world data, the two
levels of complication makes the parameters in CT-HMM even more challenging to
estimate. We are not aware of any previous work along this line and we will design a
new EM algorithm to address this challenge.
3.4.1 Challenges for learning CT-HMM
A fully observed CT-HMM contains four sequences of information: the underlying
transition time (t′0, t
′
1, . . . , t
′
V ′), the corresponding state Y = {y0 = s(t′0), ..., yV ′ =
s(t′V ′)} of the hidden Markov chain, and the observed data O = (o0, o1, . . . , oV ) at





















(In this thesis, we will focus on the estimation of the transition rate matrix Q of
the Markov chain. Those parameters in the emission model p(o|s) can be estimated
in a similar way as discrete time HMMs, as in Eqn (40c), (52-54) of [68].)
In the EM algorithm, given a current estimate of the parameter Q̂0, the expected





{log(qij)E[nij|O, T, Q̂0]− qiE[τi|O, T, Q̂0]}+
V∑
v=0
E[log p(ov|s(tv))|O, T, Q̂0].








where we need to compute the even more challenging quantity of E[nij|O, T, Q̂0] and
E[τi|O, T, Q̂0]. We show that they can be computed as:





p(s(tv) = k, s(tv+1) = l|O, T )E[nij |s(tv) = k, s(tv+1) = l, Q̂0] (19)





p(s(tv) = k, s(tv+1) = l|O, T )E[τi|s(tv) = k, s(tv+1) = l, Q̂0] (20)
where p(s(tv) = k, s(tv+1) = l|O, T ) is the probability of being in state k at visit v
and in state l at visit (v+1) given data O and T . Now the key computation of the EM
algorithm boils down to computing the posterior expectations p(s(tv) = k, s(tv+1) =
l|O, T ) and E[nij|s(tv) = k, s(tv+1) = l, Q̂0] and E[τi|s(tv) = k, s(tv+1) = l, Q̂0]
given Q̂0. All these quantities are challenging to compute. Computing the posterior
state probabilities p(s(tv) = k, s(tv+1) = l|O, T ) requires considering all possible
state transition sequences from k to l, as well as the variable time intervals between
each transition. Similar high-dimensional integrals are also needed for computing
the end-state conditioned statistics, E[nij|s(tv) = k, s(tv+1) = l, Q̂0] and E[τi|s(tv) =
k, s(tv+1) = l, Q̂0]. We now present our solution to these challenges.
Posterior State Probability at Observation Time p(s(tv) = k, s(tv+1) = l|O, T ):
During the computation of this quantity, it is important to avoid explicit enumera-
tion of all possible state assignments and variable time intervals. In order to efficiently
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tackle this problem, we note that the posterior state probabilities are needed only for
the times where we observed the data. We will exploit this key characteristic to tackle
the problem by constructing a discrete time-inhomogeneous hidden Markov model.
More specifically, given current estimate Q̂0, O and T , we will divide the time into
V intervals, each with duration τv = tv−tv−1. Then make use of the Markov property,
we will associate each interval with a state transition matrix P (τv) := e
Q̂0τv . Together
with the emission model p(o|s), then we have a discrete time-inhomogeneous hidden









The above discrete-time Markov chain allows us to reduce the computation of p(s(tv) =
k, s(tv+1) = l|O, T ) to familiar operations. The forward-backward algorithm can be
used to compute the posterior probability of the hidden states [68] (referred as soft
approach). The Viterbi algorithm can also be used to obtain a maximum-a-posteriori








and approximate the desired quantity by only using the MAP state sequence referred
as hard approach).
Note that our discretization here calculates exact statistics and is efficient. The
time inhomogeneous transition matrix P (tauv) = exp(Qtauv) between two visits sum-
marizes all possible hidden transition paths and times between every end-state pair
given a time interval, and the dynamic programming efficiently summarizes probabil-
ities of all possible hidden states at observation times.
End-State Conditioned Statistics of CTMC: In Section 3.2.1, we have ex-
plained three methods to compute the end-state conditioned statistics E[nij|s(tv) =
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k, s(tv+1) = l, Q̂0] and E[τi|s(tv) = k, s(tv+1) = l, Q̂0], which are Eigen, Expm, Unif
methods. Eigen method can only be stable when Q matrix is diagnalizable, which
may often not be the case during EM learning. The two other recently-discovered
alternatives [25], one is based on performing matrix exponential (Expm method) on
a double-sized auxiliary matrix [89], and another is called uniformization method,
which origins from the uniformization theory to connect CTMC and DTMC, both
have not been explored or studies for CT-HMM before.
In the next Section, we will propose novel EM learning algorithms considering dif-
ferent combinations of the above methods and explore the best choices under different
criteria and data properties.
3.5 EM algorithms for CT-HMM
The main EM algorithm is shown in Algorithm 1. Depending on the combination of
the hard/soft assignment during the discrete time-inhomogeneous HMM stage, and
the three different approaches of computing the end-state conditioned statistics, we
will obtain many different variants of the EM algorithm for CT-HMM. We will use
the term Soft and Hard to represent that it is soft/hard decoding of the hidden states
for the actual visits.
Algorithm 1 CT-HMM Parameter learning (Soft/Hard)
1: Input: data O = (o0, ..., oV ) and T = (t0, . . . , tV ), state set S, edge set L
2: Output: transition rate matrix Q = (qij)
3: Find all distinct time intervals t∆, ∆ = 1, ..., r, from T
4: Compute P (t∆) = e
Qt∆ for t∆ ⇒ O(rS3)
5: repeat
6: Compute p(v, i, j) = p(s(tv) = i, s(tv+1) = j|O, T ) = p(v, i, j), for v =
0, ..., V − 1, and the complete/state-optimized data likelihood l by using
Forward-Backward(soft)/ Viterbi(hard) ⇒ O(V S2)
7: Create soft count table C(∆, i, j) from p(v, i, j) by summing prob. from visits
of same t∆
8: Use Expm, Unif or Eigen algorithm here
9: Update qij =
E[nij |O,T ]
E[τi|O,T ] , and qii = −
∑
i 6=j qij
10: until likelihood converges
46
Once the MLE solution has been found, the approximates standard errors of
the parameters can be derived from the inverse of the matrix of second derivatives
(Hessian) of the log-likelihood function at the maximized solution, which can be
computed by using finite differences [26].
3.5.1 Algorithm: Soft(Expm), Hard(Expm) EM
Algorithm 2 shows the algorithm that uses the Expm method for compute end-state
conditioned statistics. In Algorithm 1 line 7, we group probabilities from successive
visits of same time interval and same specified end-states in order to save computation
times. In Algorithm 2, we put the loop for different time intervals (line 2, 8) within
the loop for each state and edge (line 1, 7) on purpose. As the A matrix does not
change with time t∆, if use scaling and squaring method [23] for expm operator (used
in Matlab), one can easily modify the expm(A) function to be expm(A, t) = etA and
caches the intermediate results of A2, A4, and A6 to be reused for computing etA for
a different t. The overall time complexity per iteration is in line 13, where r is the
number of distinct time interval, S is the number of states, and L is the number of
edges.
Algorithm 2 Expm Algorithm
1: for each state i in S do










4: E[τi|O, T ] + =
∑
(k,l)∈LC(∆, k, l)Di(k, l)
5: end for
6: end for
7: for each link (i, j) in L do











10: E[nij |O, T ] + =
∑
(k,l)∈LC(∆, k, l)Nij(k, l)
11: end for
12: end for
13: Soft/Hard: O(r(2S)4 + rL(2S)3)
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3.5.2 Algorithm: Soft(Unif), Hard(Unif) EM
In Algorithm 3, we used Unif method for compute end-state conditioned statistic for
CTMC in Algorithm 3. In line 6 and 10, Sk→l (and Lk→l) represents the intermediate
states (edges) that can be passed from state k to l. The state accessibility table can be
precomputed using Dijkastra’s shortest path algorithm in O(S2). The main benefits
of Unif in evaluating all expectations is that the R power series (R,R2, ..., RM̂), can
be precomputed (line 2) and reused, so that no additional matrix multiplications is
needed.
One main property of Unif in evaluating expectation is its O(M2) complexity,
which is not related to state space size S. It can also evaluate the expectations for
just the two specified end-states. In hard EM the soft count table C(∆, k, l) (in line 5)
becomes sparse (≤ min(V, rS2) entries have positive values), and thus Unif in hard
EM becomes more time efficient than soft EM. One possible downside of Unif is that
if q̂it is very large, so is the truncation point M , then the computation can become
very time consuming. Thus, we find that Unif ’s running time performance highly
depends on the data and the underlying Q values. The time complexity analysis is
detailed in Algorithm 3 line 16.
3.5.3 Algorithm: Soft(Eigen), Hard(Eigen) EM
In Algorithm 4, the Eigen method is presented. Eigen method also has the flexibility
in evaluating the expectations only for the specified end-states, and thus it can be
more efficient in hard than in soft EM. The main problem of Eigen is that it is not
a stand-alone algorithm. When Q is not diagonalizable in any iteration, one needs
alternative methods for that run.
3.5.4 Comparison of time complexity of all methods
The time complexity comparison of all methods is listed in Table 3. When comparing
Soft EM methods, we find that S(Expm) has better time complexity than S(Eigen)
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Algorithm 3 Unif Algorithm
1: Set t̂ = max t∆; set q̂ = maxiqi.
2: Let R = Q/q̂ + I. Compute R,R2, ..., RM̂ , M̂ = p4 + 6
√
q̂t̂+ (q̂t̂)q ⇒ O(M̂S3)
3: for ∆ = 1 to r do
4: M = p4 + 6
√
q̂t∆ + (q̂t∆)q; set t = t∆
5: for each C(∆, k, l) 6= 0 do
6: for each state i in Sk→l do












8: E[τi|O, T ]+ = C(∆, k, l)E[τi|s(0) = k, s(t) = l]
9: end for
10: for each link (i, j) in Lk→l do













16: Soft: O(M̂S3 + rS3M2 + rS2LM2); Hard: O(M̂S3 +min(rS2, V )SM2 +min(rS2, V )LM2)
Algorithm 4 Eigen Algorithm
1: Perform eigendecomposition: Q = UDU−1 ⇒ O(S3)
2: for ∆ = 1 to r do
3: Compute matrix Ψ with t = t∆ ⇒ O(S2)
4: for each C(∆, k, l) 6= 0 do
5: for each state i in Sk→l do











7: E[τi|O, T ]+ = C(∆, k, l)E[τi|s(0) = k, s(t) = l]
8: end for
9: for each link (i, j) in Lk→l do















15: Soft: O(rS5 + rLS4); Hard: O(min(rS2, V )S3 +min(rS2, V )LS2)
(one less order of S). It is because Expm can efficiently compute expectations for one
intermediate state/edge for all possible two end-states in a single operation O((2S)3),
while S(Eigen) computes for every two end-states separately O(S4).
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The comparison between Expm and Unif depends on the relative scale between
state space S and M2, where M = p4 + 6
√
maxi qit + (maxi qit)q. Expm is less
sensitive to maxi qit than Unif method (log versus quadratic dependency), because
when Expm is evaluated using the scaling and squaring method [23], the number of
matrix multiplications depends on the number of doing scaling and squaring, which
is plog2(||Qt||1/θ13)q, where θ13 = 5.4, the Pade approximant with degree 13, is used
if scaling of Q is required [23]. Then we have log2(||Qt||1) ≤ log2(maxi qiSt). Thus,
the running time of Unif will change according to max qit more dramatically than
Expm method. We believe that Expm is the most robust under soft EM.
Table 3: Time complexity comparison of all methods in evaluating the required ex-
pectations under Soft/Hard EM (r: number of distinct time interval, S: number of
states, L: number of edges, V : number of visits, M : the truncation point for Unif,
set as p4 + 6
√
q̂t∆ + (q̂t∆)q, where q̂ = maxi qi).
complexity Expm Unif Eigen
Soft EM O(r(2S)4 + rL(2S)3) O(M̂S3 + rS3M2 + rS2LM2) O(rS5 + rLS4)
Hard EM O(r(2S)4 + rL(2S)3)
O(M̂S3 + min(rS2, V )SM2
+ min(rS2, V )LM2)
O(min(rS2, V )S3
+ min(rS2, V )LS2
3.6 Experimental results
In this section, we demonstrate the performance of the presented methods on both
synthetic data and real-world dataset. The learning accuracy and running time will
both be assessed. To evaluate learning accuracy of qij, we calculate the relative
2-norm error as:




where q̂ is a vector contains all learned qij parameters, and q is the ground truth. The
convergence criteria is that the relative data likelihood change |L̂i−L̂i−1|
L̂i−1
≤ tolerace,
where the tolerance is set to 10−8 in most of our experiments.
In Section 3.6.1, we describe our procedure in generating the synthetic data. In
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Section 3.6.2, we test the learning accuracy w.r.t. varying sampling intervals of ob-
servations using Soft(Expm) method. In Section 3.6.3, we test the accuracy of all
learning methods under different levels of observational noises on a 5-state complete
digraph. In Section 3.6.4, we test the running time performance of all methods on a
2-D gridded forwarding model of 100 states.
In Section 3.6.5, we test CT-HMM’s ability in predicting future measurements
for Glaucoma progression using a 2-D gridded forwarding model. Finally, in Section
3.6.6, we learn the state transition trends using a real dataset of Alzheimer’s disease
with a 3-D gridded forwarding model. The running time performance of all methods
on both dataset will be compared. Insights are gained in visualizing the trends of
disease progression, which also support the current understanding of the diseases.
3.6.1 Procedure in generating synthetic data
To produce synthetic dataset, the first step is to generate a synthetic rate matrix Q.
Our procedure is listed in Algorithm 5. One can input a desired range [ha hb] for
the holding time parameters qi, excluding 0 for the absorbing state. For simulation
purpose, it may be better that the ratio hb
ha
to be not high, so that when generate
synthetic data sequences given a total duration, one doesn’t just stuck in one state
which has large holding time, but can have more overall state jumps. We find that
setting the ratio to be 5 is a reasonable choice for experiments.
After setting up Q, we will draw many realizations of the state chains and then the
observations from the states. Our procedure for generating the underlying CTMCs
is in Algorithm 6. Both the state and its duration are sampled based on the Q
matrix. The initial state is sampled based on an input initial state distribution π.
The duration τi for the current state i is sampled based on the exponential distribution
on the holding time parameter qi: f(t|µ = 1/qi) = 1µe
−t
µ = qie
−tqi . The next state is
sampled based on the instantaneous transition probability: vij =
qij
qi
. We sample the
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Algorithm 5 Procedure: Generate the synthetic rate matrix Q
1: Input: State set S, edge set L, range of holding time parameter qi = [ha hb]
2: Output: Q = {qij}
3: for each state i not absorbing state do
4: Sample qi uniformly from [ha hb]
5: end for
6: for each state i in S do
7: for each edge (i, j) in L do
8: Sample a random value aij uniformly from [0 1]
9: end for
10: Set rate qij values as: qij = qi
aij∑
j,j 6=i aij




chain until the specified total time has been reached.
Algorithm 6 Procedure: Sample a random CTMC
1: Input: a total time T , transition rate matrix Q, initial state distribution π
2: Output: a CTMC M = {(s1, τ1), (s2, τ2), ...}
3: Sample the first state i based on π
4: repeat
5: Sample the duration τi for the current state i based on the exponential distri-




6: T = T − τi
7: if T > 0 then
8: Sample the next state j based on instant transition probability vij = qij/qi.
Set current state i = j
9: end if
10: until T ≤ 0
After a CTMC has been realized, we generate observations with respect to a
specified sampling interval [∆a ∆b]. The procedure is listed in Algorithm 7. Given
the last observed time tk, the next observation time will be given by tk+1 = tk + ∆
where ∆ is uniformly drawn from [∆a ∆b]. Given the sampled time, the corresponding
hidden state is first mapped, and then the observational data from this state is drawn
from its data emission model p(o|s). In our simulations, we use a simple Gaussian
distribution N(µ, σ) as the data emission model.
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Algorithm 7 Procedure: Sample observations from a CTMC
1: Input: a CTMC M = {(s1, τ1), (s2, τ2), ...}, observation time interval [∆a ∆b],
data emission models p(o|si)
2: Output: observations
3: Set T = M ′s total duration; set current time t = 0
4: repeat
5: Find the underlying state i at time t from M
6: Sample an observation from state i’s data emission model p(o|si)
7: Sample a time interval ∆ uniformly from [∆a ∆b]
8: Set t = t+ ∆
9: until t ≥ T
3.6.2 Simulation 1: parameter accuracy under different sampling inter-
vals
In this experiments, we test the learning accuracy of Soft(Expm) method under differ-
ent sampling intervals, each with the same total number of observations. The purpose
of this experiment is to study the influence of sampling rate to the learning accuracy.
We set τ1 = 0.5
1
maxiqi
(half of the smallest mean holding time of states from Q),
representing a dense sampling scenario. This sampling rate setting is inspired by the
Nyquist-Shannon sampling theorem [94] from the field of digital signal processing,
which is a a fundamental bridge between continuous-time signals (”analog signals”)
and discrete-time signals (”digital signals”). It establishes a sufficient condition be-
tween a signal’s bandwidth and the sampling rate that allows discrete samples to
capture all the information from the continuous-time one. 1 It expresses the suffi-
cient sample rate in terms of the bandwidth for the referred class of functions: for a
given sample rate fs, perfect signal reconstruction is guaranteed possible for a band-
limit function of frequency B ≤ fs
2
[94].
We thus set the sampling interval τ1 = 0.5
1
maxiqi
to mimic the Nyquist-Shannon
sampling rate, set τ0 = 0.5τ1 for testing even denser sampling, and set τ2 = 2τ1
and τ3 = 4τ1 to test coarser sampling intervals. We test on a 5-state complete
1 Strictly speaking, the theorem only applies to a class of functions having a Fourier transform
that is zero outside of a finite region of frequencies [94].
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Table 4: Learning errors and convergence behavior of Soft(Expm) method under
different sampling intervals of observations. The results are averaged from 5 random
runs. The sampling interval τ1 = 0.5
1
maxiqi
(half of the smallest mean holding time of
the ground truth Q), τ0 = 0.5τ1, τ2 = 2τ1, and τ3 = 4τ1. For each setting, the number
of observation is fixed to be = 106. Convergence criteria: relative data likelihood
change ≤ tol, where tol = 10−5 or 10−8.
tol = 10−5 τ0 τ1 τ2 τ3
mean 2-norm err 0.0115 0.0167 0.0393 0.1679
std 2-norm err 0.0020 0.0028 0.0073 0.0157
ave num of iter 10 14 28 70
tol = 10−8 τ0 τ1 τ2 τ3
mean 2-norm err 0.0093 0.0094 0.0103 0.0193
std 2-norm err 0.0006 0.0010 0.0073 0.0025
ave num of iter 40 79 161 620
digraph, which has 20 unknown qij parameters. The ground truth Q matrix is set to
have the same holding time parameter qi = 1 such that the sampling rate is equally
dense/coarse for every state. The total number of observations is fixed to be = 106
for each different sampling rate.
The experimental results are listed in Table 4 by using Soft(Expm) method. In
both convergence tolerance settings (tol = 10−5 and 10−8), the sampling rate τ1 result
in around 1% of errors though its performance is worse than the denser sampling rate
τ0. When the tolerance is set to 10
−8, τ2 and τ3 can also achieve low error rates,
but the convergence speed is much slower than τ1. As τ1 gives good reconstruction
results, we will use τ1 = 0.5
1
maxiqi
for the rest simulation experiments.
In Fig. ?? , we show the error rates of the Soft(Expm) method under different
number of total observations (103, 104, ..., 107) using tol = 10−5.
3.6.3 Simulation 2: a 5-state complete digraph with varying noise levels
We then test the learning accuracy of all methods, Soft(Expm), Hard(Expm), Soft(Unif),
and hard(Unif), and Soft(Eigen), Hard(Eigen), on a 5-state complete digraph, which
has a directed edge between each state pair (20 qij parameters to be estimated). The
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Figure 26: Relative 2-norm error w.r.t. different observation counts




ground truth Q matrix is set up such that each qi is randomly drawn from [1 5]
and then qij is drawn from [0, 1] and renormalized such that
∑
j 6=i qij = qi. The





is the largest mean holding time. The data emission model
for state i is set as N(i, σ2) with σ = 1/4, 3/8, 1/2, 1, and 2 to test the performance
under different noise levels. The observations are then sampled from the state chains




is the smallest mean holding time, which
should be dense enough to make the chain identifiable. A total of 105 observations
are sampled.
The simulation results from 5 random runs are listed in Table 5. All methods
achieves low error rates when the noise level is low (sigma = 1/4). (Eigen fails at
least once for each setting but when it works, it produces similar results as the other
two). We find that all Soft methods achieve significantly better accuracy than Hard
methods, especially when the noise level becomes higher, suggesting that doing soft
is superior to doing hard. This can be contributed to the maintenance of the full
hidden state distribution which makes it more robust to noise influence.
The convergence behavior of all methods under low noise level sigma = 1/4 from
2 random runs are shown in Fig. 27, where we can see that Expm and Unif method
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Table 5: The average 2-norm relative error from 5 random runs on a 5-state complete
digraph with varying noise levels (sigma in the data emission model N(µ, σ2) where
mu is set to the state index). Number of observations is 105. Convergence when
relative data likelihood change ≤ 10−8. Eigen fails at least one run for each setting
(but when it works, it produces similar results as the other two).
Error σ = 1/4 σ = 3/8 σ = 1/2 σ = 1 σ = 2
S(Expm),S(Unif) 0.0261±0.0080 0.0324±0.0080 0.0420±0.0118 0.1990±0.0835 0.5096±0.1037
H(Expm),H(Unif) 0.0314±0.0089 0.1968±0.0622 0.4762±0.0995 0.8568±0.0801 0.9249±0.0298
has overlapped curves on either hard or soft setting while Eigen converges a bit slower
but finally achieve similar results to the other two. This phenomenon is observed in
all runs when Eigen works.
3.6.4 Simulation 3: a large 2-D forwarding model
In this experiment, we test the performance of all proposed EM methods as well as a
baseline method, called Nest-Viterbi (and denoted it as H(NestV)), that we developed
in [52], on a 2-D forwarding model of 100 states (10 × 10 grids of states). The 2-D
model structure is illustrated in Fig. 28(a). The purpose of this experiment is to
understand the accuracy as well as the time efficiency of each method for large state
space setting with sparse edge structures.
To set up the ground truth rate matrix Q, we set the holding time parameter qi
to be in the range [1 2] except the absorbing state. The remaining parameters are
set according to the procedure (Algorithm 5). We generate longitudinal sequences
as follows. First, an initial state is uniformly drawn from the state space. We then
sample the state chain until the chain has duration T = 10
miniqi
. The data emission
model for state at position (i, j) is set as N((i, j), (0.25, 0.25)). We generate the
observations using 50 distinct sampling interval r = 50, but each interval is around
half of the smallest mean holding time (( 1
maxiqi
×0.5)× (1+0.1rand()).The procedure
is repeated until we have a total of 5× 105 observations.




Figure 27: Convergence behavior of different learning methods on two random runs
for the experiment of a 5-state complete digraph. Convergence tolerance 10−8. Expm
(blue line) and Unif (green line) are almost overlapped in the graph and Eigen (ma-
genta line) method has a relatively slower convergence rate than the other two meth-
ods, possibly due to the residue error in eigen-decomposition applied on an arbitrary























































Figure 28: (a) The 2D state structure for glaucoma progression analysis [52]. The blue
arrows are the allowed instantaneous transition (qij ≥ 0). (b) An example of hidden
state decoding in Nest-Viterbi method. The blue path represents the decoded states
for the visiting data (v1, v2, v3, v4). The green path represents a possible inner state
path between the two non-adjacent decoded states for visit 2 and 3. The duration t
between visit 2 and 3 is uniformly distributed to the intermediate states for a coarse
probability evaluation.
present the experimental results in Section 3.6.4.2.
3.6.4.1 Baseline method: Nest-Viterbi
We developed an EM algorithm, named Nest-Viterbi EM [52], for the multi-dimensional
forwarding disease model to coarsely estimate the Q parameters, with simplified as-
sumptions on state transition timing and duration. This method is used as a baseline
for performance comparison. The main idea is to use Viterbi decoding to find both
the outer and the inner hidden state sequence, where the outer state sequence cor-
responds to the actual visits, while the inner state sequence is derived by decoding
of the intermediate states for any two successive outer states which are non-adjacent
(no direct edge). For any two successive decoded outer states, if they are adjacent,
we assume that the state transition happens exactly at the second visit. If the two
states are not adjacent, we find the most probable inner state sequence with a con-
straint that each intermediate state occupies the same duration. This assumption is
reasonable if the holding time for adjacent states is generally smoothly changed.
With predetermined transition timings, we can then easily apply Viterbi decoding
to find the assumed most probable intermediate states. In more detail, we determine
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Table 6: Performance comparison between all the methods on the 2-D forwarding
model of 100 states (10× 10 grids) of 297 qij parameters. Number of observations is
5 × 105. Number of distinct time intervals r = 50. Convergence tolerance = 10−5.
Eigen method fails in this experiment.
S(Expm) S(Unif) H(Expm) H(Unif) H(NestV)
2-norm err 0.0587 0.0587 0.0600 0.0600 0.1491
num of iter 7 7 6 6 5
time in precomp 0 s 0.18 s 0 s 0.18 s 0.28 s
time in outer 120 min 120 min 60 min 60 min 60 min
time in inner 4.3 min 50 min 4.3 min 3.5 min 33 sec
the most probable inner path Skl between state k and l, by requiring that intermediate
states are distinct and adjacent with same duration (i.e., the total duration t is divided
uniformly into each intermediate state) (illustrated in Fig. 28(b)). This can be





gkl is the set of all possible lengths of intermediate state paths between states k and
l. After deriving the single best state path for all subjects, each qij parameter can
then be updated using the total transition counts through link (i, j) divided by the
total duration at state i.
3.6.4.2 Results
The results are listed in Table 6. Similar to the 5-state experiments, soft approach
performs better than hard approach in terms of accuracy. The H(NestV) method
results in the largest error, which may be contributed to its restrictive assumptions
on state transition timing and consideration of only one best state path for the actual
visits and also in between two decoded outer states, rather than the full distributions
or the expectations.
In terms of running time performance, it is as expected that doing soft in the
outer layer has doubled time of doing hard, as soft needs both forward and back-














































Figure 29: (a) The 2-D gridded state structure for glaucoma progression modeling. (b)
Illustration of the prediction procedure. (c) Convergence behavior on the Glaucoma
dataset.
decoding. When compare S(Expm) and S(Unif) in time required to compute expec-
tations, Expm is more time efficient than Unif (4.3 min versus 50 min). (If we try
to generate a random initial Q matrix to make Eigen feasible, the running time is
40 minutes in computing expectations). The better time efficiency of S(Expm) can
be contributed to its efficiency in deriving expectations for one specified intermedi-
ate transition/duration from all possible end-state pairs, using just a single matrix
exponential operation. Our results show the benefits of Expm in soft EM learning.
We now compare the time efficiency between H(Expm) and H(Unif). When doing
hard in the outer layer, one can expect a sparse structure in the count table C(∆, k, l)
(number of counts the data are in starting state k and in ending state l after time t∆).
Because Unif can evaluate only the expectations specified by the required end-states
from the best decoded paths, Unif can be more efficient than Expm in hard decoding
approach. Our results in Table 6 shows that H(Unif) runs faster than H(Expm) in
this experiment.
3.6.5 Real data: prediction of Glaucoma progression
We then apply CT-HMM to visualize and predict Glaucoma progression using a real
Glaucoma dataset. Glaucoma is a leading cause of blindness and visual morbidity
worldwide [36]. This disease is characterized by a slowly progressing optic neuropathy
with associated irreversible structural and functional damage. There are conflicting
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findings in the temporal ordering of detectable structural and functional changes,
which confound glaucoma clinical assessment and treatment plans [97]. Here, we
use a 2-D gridded state space defined by successive value bands of the two main
glaucoma markers, Visual Field Index (VFI) (functional marker) and mean RNFL
(Retinal Nerve Fiber Layer) thickness (structural marker) with forwarding links (see
Fig. 29(a)), to understand glaucoma progression as well as to test the predictive
power of the CT-HMM method.
Our glaucoma dataset contains 101 glaucomatous eyes from 74 patients followed
for an average of 11.7±4.5 years, and each eye has at least 5 visits (average 7.1±3.1
visits). 63 distinct time intervals are found. The state space is created so that most
states have at least 5 raw measurements mapped to it. The states which are in
the straight path in between two successive raw data are instantiated, resulting in
105 states. The data emission model is set as a normal distribution with µ set to the
center of the data band, and σ set to 0.25 of the band width. Ten-fold cross validation
is used Testing proceeds by decoding the first 4 visits using the learned CT-HMM
model and then predicting future states and observations.
In order to compare our prediction results to current state-of-the-art methods used
in Glaucoma literatures which produce continuous measurements, we also design a
simple procedure to generate future continuous measurements, which is described as
below and illustrated in Fig. 29(b). Given a testing patient, Viterbi decoding [68] is
used to decode the hidden state path for the past visits. Then, given the future time
t, the most probable future state is predicted by j = maxj Pij(t) (blue node), where i
is the current state (black node). To predict the continuous measurements, for each
disease marker separately, we search for the future time t1 and t2 when the patient
enters a state which has same data range and next data range compared to state
j, respectively. Both t1 and t2 can be found in a desired time resolution by binary
searching. The measurement at time t can then be computed by linear interpolation
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Table 7: Running time comparison for all the methods for the real glaucoma dataset
(Eigen method fails in this experiment).
Time S(Expm) S(Unif) H(Unif)
time/iter 18 min 105 min 2 min
between t1 and t2 and the two data bounds of state j ([b1 b2] in Fig. 29(b)).
The mean absolute error (MAE) between the predicted values and the actual
measurements was used for performance assessment. The performance of CT-HMM
was compared to both the conventional linear regression and Bayesian Joint Linear
Regression [62]. For Bayesian method, the joint prior distribution of the four pa-
rameters (two intercepts and two slopes) computed from the training set [62] is used
alongside with the data likelihood.
In terms of running time, S(Expm) spends around 18 minutes in each iteration
on a 2.67 GHz machine with unoptimized MATLAB code (As a comparison, S(Unif)
spends 105 minutes in the first iteration and becomes even slower later on; H(Unif)
spends an average of 2 minutes per iteration, while Eigen fails). One fold of the
convergence behavior of CT-HMM learning using S(Expm) is shown in Fig. 29(c).
The prediction results are shown in Table 8. Our results show that CT-HMM sig-
nificantly outperforms both competing methods. This may contribute to the gridded
state-based structure in our 2-D CT-HMM that can flexibly capture the complex non-
linear interaction between the two markers at each combinatorial disease state. In this
experiment, we find that S(Expm) and H(Unif) achieve similar performance, while
H(Unif) can have much less running time. This suggests that for very large dataset
and large state space, H(Unif) may be a reasonable alternative than conducting soft
EM learning to trade accuracy with time.
In Fig. 30(a), we visualize the model trained using the entire dataset. Several
dominant paths can be identified: there is an early disease phase with RNFL thin-
ning with perfect vision (blue vertical path in the first column), and at around RNFL
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Table 8: The mean absolute error (MAE) of predicting the two future measurements
(VFI, RNFL) using our 2-D CT-HMM, Bayesian Joint Linear Regression (BJLR)
[62], and the conventional linear regression (LR) method. T-test results show that
our method performs significantly better than both the competing models.
MAE H(Unif) S(Expm) BJLR LR
VFI 4.51 ± 10.38 4.64 ± 10.06 5.57 ± 11.11 7.00 ± 12.22
RNFL 7.09 ± 6.49 7.05 ± 6.57 9.65 ± 8.42 18.13 ± 20.70
range [80, 85] the transition trend reverses and VFI changes become more evident
(blue horizontal paths). This L shape in progression supports the finding in [95]
that RNFL thickness of around 77 microns acts as a tipping point at which func-
tional deterioration became clinically observable with structural deterioration. Our
2D CT-HMM model efficiently visualize the non-linear relationship between struc-
































(a) Glaucoma progression (b) Alzheimer's disease progression
Figure 30: Visualization scheme: (a) The strongest transition among the three in-
stantaneous links from each state are shown in blue while other transitions are drawn
in dotted black. The line width and the node size reflect the expected count. The
node color represents the average sojourn time (red to green: 0 to 5 years and above).
(b) The vis scheme is similar to (a) but the strongest transition link from each state
is color coded as follows: Aβ direction only (blue), hippo only (green), cog only (red),
Aβ+hippo (cyan), Aβ+cog (magenta), hippo+cog (yellow), Aβ+hippo+cog(black).
The node color represents the average sojourn time (red to green: 0 to 3 years and
above).
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Table 9: Running time comparison for all the methods for the Alzheimer’s dataset
(Eigen method fails).
Time S(Expm) S(Unif) H(Unif)
time/iter 17 min 48 min 2 min
3.6.6 Real data: exploratory analysis on Alzheimer’s disease
In this experiment we demonstrate the use of CT-HMM as an exploratory tool to
visualize and understand the temporal interaction of disease markers for Alzheimer’s
disease (AD). AD is an irreversible neuro-degenerative disease that results in a loss
of mental function due to the degeneration of brain tissues [84]. An estimated 5.3
million Americans have AD, yet no prevention methods or cures have been found
[84]. It will be beneficial to understand the relationship among clinical, imaging,
biochemical markers as well as genetic factors on the entire spectrum of AD as the
pathology evolves, which may aid in preventing AD and developing treatments.
In this experiment, we analyze the temporal interaction among the three kinds of
markers: amyloid beta (Aβ) level in cerebral spinal fluid (CSF) (biochemical marker),
hippocampus volume (structural marker), and ADAS cognition score (functional
marker) over the course of the disease. We obtained the ADNI (The Alzheimers
Disease Neuroimaging Initiative)1 dataset from the website [84]. The mild cognition
impairment (MCI) and AD patients who have at least two visits of all three indicated
markers are included, which results in 206 subjects of 2.38 ± 0.66 visits traced in
1.56± 0.86 years with only 3 distinct time intervals in month resolution. A 3-D grid-
ded state space with forwarding links is defined such that for each marker, we have 14
bands that span its value range. The procedure for constructing the state space and
the definition of data emission model is the same as in the Glaucoma experiment. 277
states are instantiated and the model is then trained using Soft(Expm) (the running
time comparison from different methods is shown in Table 9).
The 3D visualization result is shown in Fig. 30(b). The state transition trends
64
show that the abnormality of Aβ level emerges first (blue lines) when cognition scores
are still normal. Hippocampus atrophy happens more often (green lines) when Aβ
levels are already low and cognition has started to shown abnormality. Most cognition
degeneration happens (red lines) when both Aβ levels and Hippocampus volume are
already in abnormal stages. Our quantitative visualization results supports the recent
findings that the decreasing of Aβ level in CSF is an early marker before detectable
hippocampus atrophy in cognition-normal elderly [17]. Our results show that CT-
HMM disease model armed with 2D/3D interactive visualization functions can be
utilized as an exploratory tool to gain insights of the disease progression and generate
hypothesis to be further investigated by medical researchers.
3.7 Future work: incorporation of covariate effects
In studying disease progression, it is often of interest to explore the effects of additional
explanatory factors (covariates) on the disease state transition, such as age, age of
the organ donor, the existence of a related disease/symptom, etc. These effects could
be global (disease state independence), state-dependent, or/and time-varying. Cox
proportional hazard model [57] [28, 29] can be used to relate the transition intensities
qij(t) and covariates z(t) at time t through a generalized regression form as:
qij(t, z(t)) = qij,be
WTij z(t),
where qij,b is the baseline rate parameters, and Wij is the weight vector for the covari-
ates for link (i, j). For time-varying covariates, it is usually assumed that the covariate
is a step function which remains constant between two observation times. [57] also
described likelihood ratio and Wald test for covariate selection and hypothesis testing.
We may estimate the baseline rate parameters qij,b and the weight vector W
(assume the same for all links here) for the covariate alternatively during the EM
iteration. We conceive one possible method and outline it as below:
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(1) Given current parameters Q(00) = {w(0), q(0)ij,b}, compute new average qij,ave.
Then, derive new baseline q
(1)



































































Then, we can compute the best w(1) by minimizing the approximation errors of
the above equation, such as using least squared errors, and summing over all qij links.
We can also weigh each link qij’s importance by their expected counts, resulting in a
weighted least square optimization problem.

















We then find the best weight vector W using standard nonlinear optimization method,
such as BFGS:
minWf(W ), such that W = [w1, ..., wK ] ≥ 0. (28)
It should be noted that alternative optimization of the two sets of parameters may
result in sub-optimal solutions. The ultimate goal is to design a method that can




In this chapter, we present novel EM algorithms for CT-HMM learning leveraging re-
cent approaches [25] in evaluating the end-state conditioned expectations for CTMC.
To the best of our knowledge, we are the first to present the comprehensive frame-
work for CT-HMM learning and utilize Expm and Unif methods in CT-HMM with
time complexity analysis against Eigen under soft and hard EM frameworks. In our
experimental results using simulation and real-datasets, we find that soft EM has
higher learning accuracy than hard EM especially when the noise level is high, and
Expm works the most efficient for soft EM approaches. In hard EM setting where one
intends to trade accuracy with time efficiency, Unif may be more efficient than Expm
as it can compute only the expectations specified by the end-states from the best de-
coded paths. Eigen is less general among the three methods due to its requirements
of diagonalizable rate matrix. We find Eigen indeed fails often in our experiments.
The developed CT-HMM algorithms are also evaluated in two real datasets on
Glaucoma and Alzheimer’s disease with applications including progression visualiza-
tion and prediction. Our learned state transition dynamics support the recent liter-
atures about the progressing mechanism of the two diseases. Our prediction results
using Glaucoma dataset outperform the state-of-the-art Bayesian joint linear regres-
sion [62] for Glaucoma progression prediction. This demonstrate the practical value




CTMC END-STATE CONDITIONED OPTIMAL STATE
PATH DECODING AND COMPUTATION OF
EXPECTED STATE DURATION
In this chapter, we will first review the prior work that tackles optimal state sequence
decoding given two end-states and a total time. We will review two possible settings
for the decoding problems. One is to find the most likely state and duration sequence
[66], and the other is to find the most probable state sequence considering all possible
duration assignments [46]. These decoding problems have practical use, such as ...
[66], and can be used in both CTMC and CT-HMM models.
For the first problem setting which inferring the most likely state and duration
sequence (a trajectory which is a sequence of states as well as the exact amount of
time spent in each state), it is noted recently [66] that this problem appears unsolved
before. [66] then solve this problem in three settings: (1) given the starting state
and a total time; (2) given both the starting state and the end state, with the total
time; (3) given a set of observed states in irregularly space times, with a total time.
The task is to seek the most likely trajectory that passes through the given states
at the specified times. The paper [66] shows that maximum likelihood trajectory
is not always well-defined if the model has a specific property (explain more later),
and this property can be checked using a polynomial time procedure. When well-
definedness holds, the author provides exact and dynamic programming algorithm
for inferring the most likely trajectories of CTMCs under the above mentioned three
settings. It is found in [66] that the most likely dwell times are often infinitessimal
and non-representative of typical system behavior.
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The second problem setting is to find the most probable state sequence only
while marginaling out the state dwell time. This setting has probability rather than
likelihood, which always exist a best solution. This problem is recently solved in
[46], which guarantee to find the best solution using a path extending and pruning
algorithm. The possible downside of the algorithm in [46] is that the time complexity
depends in a complex way of the underlying state transition matrixQ and the specified
total time. There is currently no easy time complexity analysis of the method, but it
is guaranteed to terminate in finite time.
In the second problem setting, [46] finds the optimal state sequence considering
all possible durations. [46] computes the probability of a feasible state sequence given
a total time t by solving Kolmogorov-Chapman equations using numerical methods
for ODE, and it can output the probability for a grid of time points from 0 to t,
which are used in prunning the paths in the dynamic program algorithm. In this
dissertation, we derive an efficient closed-form expression to compute the probability
of a state sequence given a total time t in O(n2) where n is the path length, when
the holding time parameters qi in the path are distinct. Our closed-form provides an
efficient method to compute the same statistics which can also be used in inference
tasks using sampled-paths [22].
In addition, in the second problem setting, it will also be useful to derive the ex-
pected state duration for each state in the optimal path. Both the state sequence and
the expected state durations can be used in applications that require trajectory com-
parison and clustering. We derive the closed-form expression for efficiently computing
these statistics when qi in the path are distinct, which has time complexity O(n
2) for
computing only one state, and O(n3) for all states in the path. Our closed-form solu-
tion doesn’t require matrix multiplication, and is more efficient than applying other
alternative methods (Expm, Unif, Eigen), which needs at least O(n3) for computing
expectation for one state.
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Our main contributions are summarized as follows:
• We derive a closed-form formulation to evaluate the total time conditioned state
sequence probability, which has time complexity of O(n2), where n is the length
of the state sequence. The direct method to compute this probability using
matrix exponential requires O(n3) time.
• We derive a closed-form formulation to compute the expected state duration
for each state given a state path and a total time. Our closed-form has time
complexity of O(n2) to compute for just one state, and O(n3) to compute for
all states along the path. The competing methods require at least O(n3) for
just one state, because these method all require matrix multiplication.
This chapter is organized as follows. In Section 4.1, we review the prior work for
CTMC end-state and time conditioned optimal state sequence decoding. In Section
4.2, we review the known closed-form formulation to compute the time-conditioned
state sequence probability using matrix exponential, and then derive our new ex-
pression to compute the same statistics without using matrix multiplication which is
more time efficient. In Section 4.3, we derive our closed-form expression to compute
the path and time-conditioned expected state duration. We will compare the time
complexity of our new closed-form to alternative methods using Expm, Unif, Eigen
on an auxiliary transition matrix in computing the same statistics.
4.1 Prior work on CTMC state sequence decoding
In Section 4.1.1, we will review the work for finding the most probable state sequence
considering all possible duration assignments, as this setting always has a best solu-
tion, and can is useful in real applications [46]. In Section 4.1.2, we will then review
the work that finds the maximum likely state and duration sequence [66] and explain
in what condition the maximum likely solution does not exist.
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4.1.1 Search for maximum probability state sequences considering all
continuous duration assignments
The setting in [46] is to search the maximum probability state sequence considering
all possible duration assignments bounded by two end-states and total duration T .
The formulation is as follows. Given a CTMC = (S,Q), where S is the state set and
Q is the transition matrix. Define the time-dependent probability of a state sequence
Pt(G) as the probability that the chain visits precisely the sequence of states in
G = (s1, ..., sn) by time t given that it starts at s1 at time 0. Let τ1, τ2, ..., τn be dwell











The goal is to evaluate Pt(G) over a time interval [0t], which needs in the path
extending and prunning algorithm [46].
To evaluate Pt(G), [46] used the Chapman-Kolmogorov equations, resulting in:
dPt(G)
dt
= qsn−1vsn−1,snPt(Ḡ)− qsnPt(G) (30)
where Ḡ is the state sequence (s1, ..., sn−1, that is, one-step shorter sequence of the
states in G. To evaluate Pt(G), one needs to solve the above linear differential equa-
tion. This equation depends on Pt(Ḡ), which obeys its own linear differential equation,
depending in part on the probability of a state sequence which is yet one step shorter.
Thus, one can find Pt(G) by solving system of linear differential equations, where the
variables are Pt((s1)), Pt((s1, s2)), ..., Pt((s1, s2, ..., sn)). The initial conditions are
Pt((s1)) = 1 and Pt((s1, ..., si)) = 0, i > 0. One can use standard numerical methods
to solve differential equations to calculate Pt(G).
Then, to find the optimal state sequence given a total time tmax, [46] proposed a
way to guide the path extending and prunning process using a notion called domi-
nance. Suppose G1 and G2 are two different state sequences with same starting and
end state. Then G1 dominates G2 if Pt(G1) > Pt(G2) for all t ∈ (0, tmax). If G is
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not dominated by any other sequence, then G is said non-dominated. [46] proves
that if the given CTMC has a finite state set, then there must be a finite number
of non-dominated state sequences given a total time tmax. Then, if the program can
list them all, and check which has the largest probability, then the maximum prob-
ability sequence is guaranteed to be found. [46] also shows that all prefixes of any
non-dominated sequence must also be non-dominated.
[46] proposes a search and prunning algorithm that enumerates non-dominated
sequences from shorter to longer, starting from the specified starting states. After
enumerating, each non-dominated sequence is evaluated to see which is the most
probable one at time tmax. Please see [46] for the detailed algorithm.
4.1.2 Search for maximum likelihood state and duration sequences
In [66], a trajectory of the CTMC is a sequence of states along with the dwell time
in all but the last state: U = (s0, τ0, s1, τ1, ..., sk−1, τk−1, sk). This represents that the
system enters state s0 at the beginning and where it stays for τ0 time, then goes to s1,
and stays for τ1 and so on. Eventually, the system hits state sk and remains there. Let
Ut = (s0, τ0, s1, τ1, ..., skt−1, τkt−1, skt) be a random variable describing the trajectory
of the system up until time t. This represents that there are kt state transitions up
until time t, where kt itself is also a random variable.
Given the initial state s, a total time t, the likelihood of a particular trajectory U
is shown as cite:
L(Ut = U |s0 = s) =

0 if s0 6= s or
∑k−1










i=0 ti > t in the first line means that the likelihood is zero if the




−qsi tivsi,si+1) represents the likelihood of the dwell time until state sk−1 and




for the probability that the dwell time in the last state does not finish before time t.
The end-conditioned most likely trajectory problem can be formulated as:
arg maxU L(Ut = U |s(0) = s, s(t) = s
′
)
where s and s
′
are the two given end-states, and t is the given total time.
• Find the most likelihood dwell time for a given state sequence: In this
setting, the optimization problem becomes:




In [66], it is shown that when given a particular state sequence, if state si has the
largest expected dwell time (i.e., has the smallest holding time parameter qi),
then the most likely setting of dwell time is derived by putting all of the time T
in state si (the slowest state), and all other transitions happen instantaneously.
This result is not unintuitive, but is dissatisfying in the sense that the resulting
most likely set of dwell time is not typical, since none are close to their expected
value.
• Find the most likely state sequence for give end-states and total time:
With the solution for the above problem that all the times goes into the slow-
est state, one can now finds the most likely state sequence that maximize the
likelihood using the derived formula:






The solution can be found using dynamic programming. In order to build
the maximum likelihood paths of increasing length, one finds the best ways of
extending the shorter paths [66]. The main difference here to other typical dy-
namic program problems is to remember not just the current score, the current
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end-state, but also the smallest holding time parameter q along the path. The
running time of this algorithm is O(K|S|3), where K is the number of state
jumps, which can be limited to be a preset value.
• Situations where maximum likelihood trajectory is not well-defined:





, than maximum likelihood trajectories do not exist. A sequence of trajectories
with ever-increasing likelihood can be found if the cycle is reachable. Thus,
before seeking the maximum likelihood trajectories from a starting state s, one
should check if the graph has a cycle having the stated property. This can
be done by setting the weight as logvs1,s2qs1 for the edge s1 to s2, and check
whether the graph contains a positive-weight cycle, which needs polynomial
time computations.
4.2 Computation of time-conditioned state sequence prob-
ability
Here, the goal is to compute the probability of a state sequence G = (s1, ..., sn) given
the total spanning time t. This can be formulated as:






τi < t ≤
n∑
i=1
τi|G = (s1, ..., sn)) (31)
where n is the length of G, vsi,si+1 is the state transition probability, and τi is the
duration in each state si.
Note that p(
∑n−1
i=1 τi ≤ t ≤
∑n
i=1 τi|G) can be evaluated using matrix exponential
on an auxiliary Q̂ matrix constructed using only the states along the state path (Eqn.
(4)(5) in [22]). In detail, if G = (s1, · · · , sn), we construct an auxiliary (n+1)×(n+1)
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rate matrix Q̂ as follows:
Q̂ =

−qs1 qs1 0 · · · 0 0
0 −qs2 qs2 · · · 0 0
· · · · · · · · · · · · · · · · · ·
0 0 0 · · · −q(sn) qsn






i,i 6=k qsk,si is the holding time parameter of state sk. This matrix has
the structure that only the transition from si to si+1 is set positive at the (i, i + 1)




τi ≤ t ≤
n∑
i=1
τi|G) = (eQ̂t)1,n (33)
which is a matrix exponential operation on the auxiliary matrix Q̂.
Closed-form formulation for the (1, n) entry of eQ̂t: We find that the (1, n)th
entry of eQ̂t has closed-form via Laplace transformation1. The results are as below
(For notation simplicity, we write qsi as qi):













• If qi, i = 1, ..., n are not distinct, without loss of generality, we assume q1 = q2 =







tp−2 + ...+ a1p)e
−q1t + Ap+1e
−qp+1t + ...+ Ane
−qnt
Below we list some steps to derive (eQ̂t)1,n when qi are distinct using Laplace Trans-
form and the Inverse Laplace Transform by Partial Fraction Expansion as below:
(eQ̂t)1,n = F−1(F((eQ̂t)1,n))
1This is a collaborative work with Shuang Li and Le Song, who derive this exact closed-form.
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where F−1 is Laplace Transform and F−1 is Inverse Laplace Transform.
F(s) = F(eQ̂t)1,n = (sI − Q̂)−11,n =
q1q2...qn−1
(s+ q1)(s+ q2)...(s+ qn)















Ai = lims→−qi(s+ qi)F(s) =
q1q2...qn−1
(−qi + q1)...(−qi + qi−1)(−qi + qi+1)...(−qi + qn)
.
Then we have













4.2.1 Comparison of time complexity
Here, we compare the time complexity of computing the state sequence probability
given a total using a direct matrix exponential method and the closed-form expression
we derived. The comparison is listed in Table 10. The direct method means that to
compute (eQ̂t)1,n by computing the matrix exponential and then read the (1, n) entry,
which needs O(n3) time. Clearly, our closed-form results only O(n2) time, but it need
that all qi are distinct.
Table 10: Time complexity comparison of all methods in evaluating time-conditioned
path probability (n: number of states in the path)
Complexity direct-expm Ours
Time O(n3) O(n2)
Prerequisite none qi distinct
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4.3 Computation of path-and-time conditioned expected state
duration
To the best of our knowledge, we have not found any literature that explicitly write
down the closed-form and methods for computing expected state duration for a path-
conditioned CTMC. We derive a closed-form formulation for computing these path-
conditioned statistics, which is applicable when qi for the states in the path are
distinct. We also compare the time complexity of using our closed-form to using the
three alternative methods (Expm, Unif, Eigen) which are originally used in end-state
conditioned cases, to compute path-conditioned statistics by applying on an auxiliary
matrix according to the state path.
We now explain our derived closed-form in detail2. Given a state sequence G =
(s1, ..., sn), a total duration t, the computation of the expected state duration τk, for
































































i 6=j qij are the holding time parameters, Q̃ is the auxiliary matrix for
2This is a collaborative work with Shuang Li and Le Song.
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the entire state path:
Q̃ =

−q1 q1 0 · · · 0 0
0 −q2 q2 · · · 0 0
· · · · · · · · · · · · · · · · · ·
0 0 0 · · · −qn qn








−q1 q1 0 · · · 0 0
0 −q2 q2 · · · 0 0
· · · · · · · · · · · · · · · · · ·
0 0 0 · · · qk qk




, and Q̃k,B is the auxiliary matrix for the partial state path from the (k + 1)th state
to the last state (the nth state):
Q̃k,B =

−qk qk 0 · · · 0 0
0 −qk+1 qk+1 · · · 0 0
· · · · · · · · · · · · · · · · · ·
0 0 0 · · · −qn qn
0 0 0 · · · 0 0

(n−k+2)×(n−k+2)













































qm−qj ) k = 1, · · · , n; j = k, · · · , n
(41)
which are derived from the closed-form expression for (eQ̃t)1,n.
Efficient computation of the expected duration for each state in the
state path: we can derive the recursive relation between ak,i and ak−1,i, and also bk,j








k = 1, · · · , n; j = k, · · · , n
(42)
Time complexity analysis: The time complexity in computing all τk, k =
1, ..., n, where n is the length of the inner path is O(n3/6). The detailed analysis is as
follows. First, the computation of all required ak,i and bk,j from the derived recursive
form needs O(n2). Second, the computation of the common denumerator requires
O(n2). Third, the computation of the numerator for one τk using the precomputed
ak,i and bk,j, requires k(n − k) = O(n2). Finally, the computation of the numerator
for all τk needs
∑n
k=1 k(n− k) = (n3 − n)/6 = O(n3/6).
Thus, evaluating just one expected state duration requires O(n2) computations,
and evaluating all expected state durations along the path needs O(n3) (n is the path
length).
4.3.1 Comparison of time complexity
We compare the time complexity of computing the expected state durations given the
state path and a total time from the three alternative methods (Expm, Unif, Eigen)
and our closed-form solution. The three alternative methods (Expm, Unif, Eigen)
are originally used in computing the end-state conditioned statistics (see more details
in Chapter 3). To use them for computing path-conditioned statistics, we only need
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to construct the auxiliary matrix Q using the state path as the new rate matrix,
and the remaining formulations are the same for calculating the end-state and path
conditioned statistics.
The time complexity comparison is listed in Table 11. Our closed-form expres-
sion have only O(n2) time in computing one expected state duration, while all other
methods require at least O(n3) as these alternative methods all involve matrix multi-
plications. When computing the expected duration for all states along the path, our
close-form method has O(n3) complexity, and is more efficient than Expm and Unif
methods. However, our method and Eigen both have prerequisite of its use, while
Expm and Unif are more general.
Table 11: Time complexity comparison of all methods in evaluating path-and-time
conditioned expected state durations. (n: number of states in the path, M : the
truncation point for Unif, set as p4 + 6
√
q̂t + (q̂t)q, where q̂ = maxi qi for states in
the path, and t: the total time).
Complexity Expm Unif Eigen Our Closed-Form
For one state O((2n)3) O(Mn3 +M2) O(n3 + n2) O(n2)
For all states O(n(2n)3) = O(n4) O(Mn3 +M2n) O(n3 + n3) O(n3)
Prerequisite none none Q diagonalizable qi distinct
4.4 An simulation example
We now show one simulation example of computing the optimal state sequence given
two end-states and a total time using the method from [46] (Matlab and R package
can be downloaded from the author’s website), and then computing the expected
state duration for each state in the optimal path using our presented closed-form and
the three alternative methods (Expm, Unif, Eigen).
In Fig. 31, we show a simple 2-state complete digraph models, with state s1 has
q1 = 1 (mean holding time = 1) and s2 has q2 = 0.5 (mean holding time = 2). Now
if we set the beginning state to be s1, the terminating state to be s2 and a total
duration = 12. What is the optimal state sequence considering all possible dwelling
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Figure 31: A simple 2-state digraph used to demonstrate the optimal state sequence
decoding and computation of the expected state duration for the optimal path.
time assignments?
The path extending and pruning method from [46] gives the solution of the
best state sequence as (1, 2, 1, 2, 1, 2, 1, 2), and our methods to compute expected
state duration given the path and total time, gives the corresponding durations as
(1, 2, 1, 2, 1, 2, 1, 2) which sums to 12. This result corresponds to our intuition of the
best state path and the expected dwelling time of this model based on the holding
time parameters qi.
4.5 Experimental results in computing path-and-time con-
ditioned expected state duration
We test the running time of computing path-and-time conditioned expected state
duration. Our setting is as follows. Given a state path of length n, each state’s
holding time parameter qi is generated randomly from [0 1]. The testing total time
T is set to be the sum of the mean holding time parameter
∑n
i=1 1/qi. We test the
running time for n = 20, 30, 40, and for each testing, 10 runs are tested and the results
are averaged.
The running time results are listed in Table 12. We find that Eigen method tends
to be the faster but fails often for n is large. Our closed-form has better running time
than Expm and Unif method in all testing cases. Unif method becomes slower when
the total time T is larger (when n is large). This is due to its quadratic dependency of
time. In terms of the accuracy results, we find that in our testing cases, all methods
can derive similar expected state duration and the durations are sum to the total
time, except the runs when Eigen method fails. However, note that our closed-form
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can only be used when each qi are distinct. Regarding to the generalizability and
running time together, Expm method appears to be the best choice.
Table 12: Running time comparison of all methods in evaluating path-and-time con-
ditioned expected state durations. For each setting, 10 random runs are tested and
the average running time is reported.
Time Expm Unif Eigen Our Closed-Form
n = 20 0.011 s 0.375 s 0.002 s 0.005 s
n = 30 0.029 s 0.876 s 0.007 s (fail: 1/10) 0.016 s
n = 40 0.061 s 18.91 s 0.012 s (fail: 5/10) 0.030 s
4.6 Conclusion and future work
In this chapter, we review the prior works for CTMC and CT-HMM in finding the
optimal state sequence considering all possible duration assignments given two fixed
end-states and a total time. Another related problem is to find the maximum likely
state and duration sequence together under same conditions. It is found that the
former problem setting can result in more biological meaningful solution, while the
solution derived from the latter setting gives all duration to the state with the largest
mean holding time (smallest qi), which is usually undesirable in practice. The exact
solution found for the first problem can be useful in real applications to understand
the best hidden path. However, the prior work didn’t present the method to compute
the expected duration for the found optimal state path.
To the best of our knowledge, we are the first to explicitly tackle the problem
of computing the path-and-time-conditioned expected state durations. While the
techniques for finding end-state conditioned expectations can be applied for the path-
conditioned one, by working on the auxiliary matrix constructed for the path, the
resulting computation may not be the most efficient. We derive the exact closed-form
for computing the following two statistics without using any matrix multiplications
but with the prerequisite that qi in the paths are all distinct. The two statistics are
(1) the probability of a state sequence given a total time, computed in O(n2), (2) the
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expected state duration given a state sequence and a total time, computed in O(n2)
for just one state, and O(n3) for all states along the path. We also compare the time
complexity of using Expm, Unif, Eigen methods to the newly-derived closed-form.
The former three methods require at least O(n3) for just one state, because these
methods all require matrix multiplication. The derived new closed-form expression,




APPLICATIONS ON GLAUCOMA PROGRESSION
MODELING USING MULTI-DIMENSIONAL CT-HMM
Glaucoma is an optic neuropathy characterized by slowly progressive loss of retinal
ganglion cells and damage of optic nerve. If left untreated, glaucoma may cause ir-
reversible visual field deficits and even blindness (see Fig. 32) [39], and thus timely
detection of disease and its progression are of paramount importance for initiating
or modifying treatment. Glaucoma has been called the silent thief of sight because
the loss of vision often occurs gradually without patients awareness until the dis-
ease has advanced significantly. It is estimated that over 2.2 million Americans have
glaucoma but only half of those know they have it [85]. This large undiagnosed pop-
ulation is mainly due to unnoticeable symptoms of early glaucoma and the difficulty
of consistently screening the entire population. In the U.S., more than 120,000 people
are blind from glaucoma [67]. Worldwide, glaucoma is the second-leading cause of
blindness after cataracts [36].
Since the visual field cannot typically be recovered, early identification of glaucoma
(a) Normal vision (b) Glaucoma
Figure 32: Comparison of normal vision and visual field with Glaucoma (From [85],
used without permission).
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Figure 33: Examples of Optical Coherent Tomography (OCT) Images of optic nerve
head. The OCT enface (left image) is a 2D image generated by projecting the 3D-
OCT volume along the z (depth) axis. The horizontal slice (right image) corresponds
to the green line in the enface. In the glaucoma case (b), the retinal nerve fiber
layer (RNFL), the topmost layer of the retina that looks bright in OCT images, is
apparently thinner than the normal case (a).
and its progression, and delivery of appropriate treatment are critical to retard the
deterioration and preserve sight. Clinically, several techniques for structural and
functional measurement are often utilized for glaucoma monitoring. For example, 3D
optical coherence tomography (3D-OCT) is used to examine the optic nerve head [43]
(Fig. 33), and psychophysical techniques, such as automated perimetry, are applied
to assess the status of the visual field [40].
Many cross-sectional studies of Glaucoma progression have demonstrated good
correspondence between structure and function and the ability to detect the disease
with high accuracy [11] [81] [98] [96] [87] [21] [79] [15]. However, longitudinal studies
have shown discordance between structural and functional changes appearing over
time, regardless of the method employed for assessing structural change [44] [59] [61]
[78] [45] [97] [60]. In many of the latter studies, structural changes were detected
prior to functional loss in a substantial percentage of eyes, while a smaller percentage
of eyes showed functional progression without detectable structural changes. This
asymmetry and asynchrony between the structural and functional progression poses
challenges for clinical assessment, resulting in inefficient treatment.
A number of prior studies tried to establish models of the relationship between
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structural and functional factors, [1] [2] [71] [3] [12]. However, none of them has
reached the level of accuracy and efficiency to be usable by clinicians to facilitate
the development of treatment plans. This is most likely because conventional glau-
coma progression analysis uses models which are based on restrictive assumptions,
such as linearity of change. With such restrictions, various potential glaucoma pro-
gression phenotypes may be recognized as noise leading to confusing or sometimes
contradictory observations.
In this dissertation, we propose to combine longitudinal structural and functional
measurements by using a 2-D CT-HMM (see Fig. 34) to decode the underlying true
disease stages. We use two hidden state dimensions, one is structural and the other
is functional, to model the composite disease status. Our 2-D state-based model can
reveal the intricate interactions between structural and functional damages without
restrictive assumptions on the form of progression, such as linearity used in conven-
tional models, and provides a useful starting point for developing a practical tool that
can identify previously undiscovered glaucoma progression phenotypes and provide
more accurate predictions of glaucoma progression.
This chapter is organized as follows. In Section 5.1, we train and visualize separate
2-D CT-HMMs for patient visit data from all ages, ages less than 70, and ages greater
than 70, using a large glaucoma longitudinal dataset. The state transition trends
are visualized and compared between these three models. We will show that our
results support a recent literature for first detectable functional changes in a particular
structural state. In Section 5.2, we test the ability of our 2-D CT-HMM for predicting
future progression of glaucoma. A simple procedure is devised to predict not only
the future state but also the continuous measurements. We compare the predictive





















Figure 34: The 2-D state structure for glaucoma progression, where one dimension
represents functional degeneration, and the other is for structure. The blue arrows
are the allowed instantaneous forward transition (qij ≥ 0).
5.1 2-D exploratory analysis using structural and functional
markers
The prevailing approach currently employed assesses glaucomatous changes occurring
either by structure or by function. Here, we first introduce a novel comprehensive
approach based on two-dimensional CT-HMM model, where one dimension is func-
tional degeneration, and the other dimension is structural degeneration, to model the
disease states and their transition behavior considering both components.
To define the state structure for glaucoma progression, we assume that the dis-
ease can only degenerate and cannot recover since glaucomatous damage is typically
irreversible. We also require that the instantaneous transitions (qij) must go to the
closest degenerative states only, which is a reasonable setting since qij represents in-
stantaneous transition. The three allowed transition links (the right, down, diagonal
link) from each state and the resulting model structure are illustrated in Fig. 34.
Note that it is also feasible to add recovering links (backward links) from each state
if desired.
Construction of MD state space and the state transition structure: We now
explain our procedure in constructing an M-D state space and the state transition
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structure. Given M kinds of measures for building an M dimensional disease model,
we define a disease state as having a predetermined value range for each measure.
A simple histogram analysis for each measure can be used to define an appropriate
value range such that most of the states have a sufficient amount of patient data
associated with them. After defining the state space, we then create the states and
their transition structure based on the dataset at hand, such that there exists a
straight continuous path between every two consecutive input data. In this way, a
compact and descriptive state space can be constructed. Note that the size of the
model varies with both the number of dimensions (M-D) and the total number of
disease states (which depends upon the number of states per dimension). From the
computational perspective, the total number of states is the primary quantity that
determines the running time of our program, and we describe below methods which
can be efficient for different numbers of states. The number of dimensions (measures)
used in the model will be chosen based on the clinical or research purpose.
5.1.1 Experimental results: transition trend visualization
For this experimental setting, 197 glaucoma suspect and glaucoma subjects were
followed longitudinally for an average of 10.4± 4.9 years, with comprehensive ocular
examination, visual field (VF) testing and optical coherence tomography (OCT). The
total number of visits with qualified VF and OCT measurements is 1048. Through
the course of the study, multiple OCT iterations were used. Calibration equations
between four OCT machines were employed to enable the use of mean retinal nerve
fiber layer (RNFL) thickness measurements as a one-parameter continuum. 2D state
space defined by using VF index (VFI) and mean RNFL is employed to evaluate
progression.
In Fig. 35, the transition results learned from all the data are shown. The strongest
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Figure 35: Visualization of the state transition trends and expected state and edge
visiting count for all patients. Visualization scheme: the strongest transition among
the three instantaneous links from each state are shown in blue while other transitions
are drawn in dotted black. The line width and the node size reflect the expected count.
The node color represents the average sojourn time (red to green: 0 to 5 years and
above).
transition among the three instantaneous links are shown in blue. The node size re-
flects the relative number of eyes, the node color reflects the average dwelling time
(red to green: 0 year to 5 years or above), the width of the link between nodes reflect
the number of observed progression along the path. Several predominant paths were
detected: early disease phase with RNFL thinning without an apparent change in
VFI (thick vertical paths), and at RNFL range [8085], the transition trend reverses
and VFI changes become more evident (blue horizontal paths). This L shape in pro-
gression supports the finding in [95] that RNFL thickness of around 77 microns acts
as a tipping point at which functional deterioration became clinically observable with
structural deterioration. We can identify several L shape dominant state transition
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(a) age group (≤ 70)
(b) age group (> 70)
Figure 36: Visualization of the state transition trends and expected state and edge
visiting count for age group (≤ 70) and (> 70). The visualization scheme is the same
as in Fig. 35.
in this figure (at (VFI:100, RNFL [85 80]), (VFI:[98-96], RNFL:[80 75]), (VFI:[96-
93], RNFL:(95 90)), etc.). At these corner point of L shapes, the model reveals that
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the functional degeneration becomes more likely than the structural changes. Our
2D CT-HMM model efficiently visualize the non-linear relationship between struc-
tural and functional degeneration, which helps understanding glaucoma progression
comprehensively.
In Fig. 36, we show the models trained by visits separated from two different
age ranges (≤ 70) and (> 70). From Fig. 36(a), we see that for younger age group,
the dominant structural changes are more apparent (the left-most vertical line) when
vision is still perfect, and when RNFL is at [90−85] there is a visual field degeneration
trend. In Fig. 36(b) for age > 70, the trend of visual field loss starts when RNFL is
at [100 − 95], which is higher than the younger group, and at the successive RNFL
ranges [95 − 90] and [90 − 85] there are also trends of visual field loss. This reveals
that for older ages, visual field is susceptible to change even when RNFL is not very
thin, while in younger ages, the visual function starts to show deficits until RNFL
thickness is at lower ranges.
Unlike the commonly used methods for longitudinal analysis, namely trend or
event analysis, the method presented here provides a comprehensive visualization
of non-linear and complex nature of structural and functional glaucoma progression
interactions. This facilitates accurate mapping of the structure and function rela-
tionship, decoding of clinical paths along the full spectrum of glaucoma severity, and
prediction of the future progression.
5.2 Prediction of future states and measurements
Our approach to trajectory prediction is based on predicting the future state with
the maximum probability, and then optionally predicting the continuous observation
data for that state. First, the Viterbi decoding algorithm is used to decode the hidden
state path for a subject based on past consecutive visits. Then the next state is given


























Figure 37: Illustration of the procedure of predicting continuous measurements at a
future work for each data dimension based on transition probability matrix. Given
the current state i at time 0, and a predicted future state at time t, then for inter-
polating the continuous value of structural marker at time t, we find time t1 when
the underlying process just enters a state with the same data range as state j, and
time t2 when the process just leaves this data range to the next level. These two time
points can be found by binary search using P (t) matrix.
a MD CT-HMM, i denotes the decoded state at the last past visit and t denotes the
time interval between the last past visit and the next future visit.
Then, in order to predict the continuous measurements for each data dimension,
we must interpolate between two predicted states with adjacent data range, since each
state is associated with a range of measurements rather than a single measurement.
For each data dimension, we identify the time t1 when the patient first enters a state
with the same data range as the predicted state j, and the time interval t2 when the
patient leaves the predicted state j and enters a state with the next adjacent data
range. Both t1 and t2 can be found by analyzing the transition probability matrix.
The measurement at time t can then be computed by linear interpolation between
t1 and t2 and their corresponding measurements. This process can be repeated to
predict subsequent states and associated measures.
5.2.1 Comparison to Bayesian Joint Linear Regression method
The main assumption of using linear regression method for prediction is that the
current rates of disease progression will remain relatively unchanged unless further
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interventions are delivered and, thus could be good predictors for future observations.
In Bayesian joint linear regression method [58], linear regression is assumed for each
response process, but the processes of each response are associated by imposing a joint
multivariate distribution on the regression parameters (two slopes and two intercepts
in Glaucoma case, a total of four parameters [58]) as the prior for influencing the
parameter estimation for each individual eye. The parameters of this multivariate
distribution as prior are estimated from the training data.
The formulation we adopt is detailed as follows [92]: Yk,i = αk + βkXk,i + εk,i
where k represents the measurement type, i represents the visit index, Xk,i is the
time of the visit, Yk,i is the measurement, α is the intercept, β is the slope, and εk,i is
the residual between the actual measurement Yk,i and the fitted value (αk + βkXk,i).




















(Yk,i − (αk + βkXk,i))2},
where K is the number of response variables, which are 2 in Glaucoma progression
model for one structural and one functional response. For the prior term, we use a
multivariate Gaussian distribution for {αk, βk}k=1,2, and an non-informative prior for
the error standard deviation term {σk}k=1,...,K . Then, for each individual eye, we can
thus find the Maximum a Posterior (MAP) estimation of {αk, βk, σk}k=1,2 by maxi-
mizing the product of the likelihood term L2 and the prior term p(αk, βk, k = 1, .., K)





Figure 38: Example results of prediction (Magenta line: linear regression; blue line:
Bayesian joint linear regression; light blue line: the ground truth global linear regres-
sion results which uses all data points; black range bar: CT-HMM decoded states for
prior visits; gray diamond: CT-HMM predictive values. From example (a-c), we can
see that CT-HMM gives reasonably good results; Bayesian method generally derives
lower slope values than linear regression ans is more robust to noise. In example (d)
we shows a failed example of CT-HMM, which overestimate the progression for VFI
due to overfitting in a state where the training data is scarce.
5.2.2 Experimental results on prediction
We have conducted an initial study to assess the prediction ability of a 2D CT-
HMM model using VFI and mean RNFL thickness for glaucoma progression (unpub-
lished data). 101 glaucomatous eyes from 74 patients were followed for an average
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Table 13: The mean absolute error (MAE) of the two measures (VFI, RNFL) using our
2D CT-HMM, Bayesian Joint Linear Regression (BJLR), and the conventional linear
regression (LR) model. T-test results show that our method performs significantly
better than both the competing models.
MAE CT-HMM (H-Unif) CT-HMM (S-Expm) BJLR LR
VFI 4.51 ± 10.38 4.64 ± 10.06 5.57 ± 11.11 * 7.00 ± 12.22 *
RNFL 7.09 ± 6.49 7.05 ± 6.57 9.65 ± 8.42 * 18.13 ± 20.70 *
of 11.7±4.5 years, and each eye has at least 5 visits (average 7.1±3.1 visits). 10-fold
cross validation was used to evaluate the prediction performance. Testing proceeded
by decoding the first 4 visits using a learned CT-HMM model and then predicting
future observations. The mean absolute error (MAE) between the predicted values
and the actual measurements was used for performance assessment. The performance
of our model was compared to both conventional linear regression and Bayesian Joint
Linear Regression. For linear regression, the individualized slope was computed from
the first 4 prior visits, while for Bayesian method, the best intercepts and slopes were
derived using both the four prior visits and the prior distribution of the parameters
computed from the training set.
Our experimental results are shown in Table 13. Our results show that our 2D CT-
HMM performs significantly better than both conventional linear regression model
and the state-of-the-art Bayesian joint linear regression model. In Fig. 38, we show
several examples of prediction results. From example (a-c), we can see that CT-HMM
gives reasonably good results, and Bayesian method generally derives lower slope val-
ues than linear regression and Bayesian is more robust to noise or natural fluctuation.
In example (d) we shows a failed example of CT-HMM, which overestimate the pro-
gression for VFI due to overfitting in a state where the training data is scarce. This
error can be mitigated when the dataset is enlarged to include more patients in severe
states. Otherwise, one may resort to using a hybrid approach, for example, using the
average of Bayesian and CT-HMM results when the predictive future path is passing
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states where the training data is insufficient.
5.3 Conclusion and future work
A novel state-based longitudinal analysis method based on multi-dimensional CT-
HMMs is proposed for modeling the asymmetric and asynchronous aspects between
structural and functional changes in glaucoma. The state-based continuous time
modeling links the discrete irregularly-spaced measurements to an underlying hidden
continuous-time process which indexes a progression in combinatorial disease states.
Its flexible state-based structure enables it to handle intricate patterns between struc-
tural and functional changes without having restrictions on the global behavior. Our
visualization results confirm the existence of a tipping point where the relationship
between structural (RNFL thickness) and functional measures (visual field measure-
ments) changes [95] with more prominent functional loss.
For predicting future continuous measurements, we devise a simple procedure
to interpolate measures by inferencing on the transition probability matrix. Our
prediction results significantly outperformed both the conventional linear regression-
based methods and the start-of-the-art Bayesian joint linear regression method [62]
for glaucoma prediction. The current clinical glaucoma management depends upon
structural and visual function measurements with pre-specified observational intervals
(typically every 6 or 12 months). With accurate state-based progression prediction,
treatment plan can then be individualized with optimized visit intervals and testing
schedules.
In sum, our promising results using M-D CT-HMM provides a useful starting point
for developing a practical tool for glaucoma that can identify previously undiscovered
progression phenotypes and may provide accurate glaucoma progression predictions.
For the future work, we propose the following two interesting directions:
M-D marker analysis: though RNFL thickness and the visual field parameters
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VFI are the most used key markers for assessing glaucoma progression, there are
many more clinical measures to assess glaucomatous damage other than these two.
Optic disc parameters (e.g. cup/disc ratio, rim area, and cup volume) are the major
ones among them. [10] [19] [74] [77] [76] [82]. They are also known to often disagree
with RNFL thickness and visual field parameters [15] [12] [8] [47] [54].
In order to get comprehensive understanding about such complicated relation-
ships, one can do pick any 2 or 3 biomarkers and analyze their relationship in the
M-D state space. The resulting M-D CT-HMMs will reveal an array of non-linear
relationships and interactions, many of them are currently undiscovered, among all
the included clinical parameters. This will provide comprehensive understanding of
the very complicated phenomenon called glaucoma progression.
Phenotype identification: National Eye Institute (NEI) defines glaucoma as a
group of diseases that can damage the optic nerve and result in vision loss and blind-
ness. In general, this group of diseases exhibits a similar path of vision deterioration,
especially in the progression of visual field loss. However, as described above, there
are many discordant reports on glaucoma progression. Therefore, it has become an
accepted concept among glaucoma specialists that there potentially exist multiple
glaucoma progression phenotypes, where a phenotype is a group of patients who are
identified as having similar characteristics of progression. The potential phenotypes
has never been scientifically and systematically identified yet.
As described above, Wollstein et al. reported a tipping point that divides the
structure-function relationship into two fits.[95]. One line fit represents a group of
eyes that have relatively thick retinal nerve fiber layer (RNFL) associated with near
healthy visual field (VF), while the other fit shows a clear linear correlation between
RNFL thickness and VF measurements. This tipping point suggests that there are 2
phases in glaucoma progression; (1) early or pre-perimetric glaucoma, and (2) once
RNFL hits the tipping point both RNFL and VF deteriorate together. These two
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phases can be viewed as two phenotypes. Pairing our analysis method with tra-
jectory clustering techniques, potential phenotypes can be identified through both
visualization by domain experts and by automated cluster analysis.
Overall, the conventional one size fits all approach to glaucoma progression mod-
eling often treats minor phenotypes as noise, missing an opportunity to describe the
atypical patterns that can improve treatments. With the guide of M-D CT-HMM
analysis with trajectory clustering methods, the detection of glaucoma progression
phenotypes will facilitate the classification of a given patient into one of the pheno-




PRELIMINARY STUDY ON ALZEHIMER’S DISEASE
AND HYPERTENSION USING MULTI-DIMENSIONAL
CT-HMM
In this chapter, we present preliminary study on Alzehimer’s disease and hypertension
progression modeling using multi-dimensional CT-HMM. For Alzehimer’s disease, we
analyze and visualize the interaction of disease markers from three distinct aspects–
structural, functional, and biochemical, over the course of disease evolution using a 3D
CT-HMM. We will analyze the results and see whether they correspond to the current
knowledge of the degeneration ordering. For hypertension, we analyze the two blood
pressures, systolic and diastolic, from electronic health records (EHR) of a cohort
population enrolled in a hypertension management program using a 2D CTHMM.
We do cluster analysis on the decoded state transition trajectories from all patients.
A novel visualization is presented to compare th states visited and transitions taken
by two different subgroups with distinctive hypertension trajectories. Our model with
visualization tools provides an interface for exploratory analysis and model validation,
and improves the interpretability of the model results for healthcare researchers.
6.1 Applications on Alzheimer’s disease progression mod-
eling
Alzheimers Disease (AD) is an irreversible neuro-degenerative disease that results in a
loss of mental function due to the deterioration of brain tissue. It is the most common
cause of dementia among people over the age of 65, affecting an estimated 5.3 million
Americans, yet no prevention methods or cures have been discovered. Recently, the
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decreasing of amyloid beta in cerebral spinal fluid (CSF) has been found to be an early
marker before detectable hippocampus atrophy. It will be beneficial to understand
the relationship among clinical, imaging, biochemical biomarker characteristics as
well as genetic factors on the entire spectrum of Alzheimers disease, as the pathology
evolves, which may aid in preventing AD and developing treatments.
Our goal is to track the progression of the disease using available bio-markers to
assess the brain’s structural, bio-chemical, and functional changes over the course of
disease evolution.
Figure 39: The current knowledge about the abnormality ordering of different
biomarkers for Alzheimer’s disease. The abnormality of amyloid beta level can be
first detected (from CSF or from F18 amyloid imaging), then the tau level (from CSF
or from PET scan), then the brain atrophy (MRI scan), then memory score, then
cognition score (from ADNI website [84], used without permission).
6.1.1 3-D exploratory analysis of structural, functional, and biochemical
markers
In this experiment, we analyze the temporal interaction among the three kinds of
markers: amyloid beta (Aβ) level in cerebral spinal fluid (CSF) (bio-chemical marker),
hippocampus volume (structural marker), and ADAS cognition score (functional
marker) over the course of the disease. We obtained the ADNI (The Alzheimers
Disease Neuroimaging Initiative)1 dataset from the website [84]. The mild cognition
impairment (MCI) and AD patients who have at least two visits of all three indicated
markers are included for our analysis, which results in 206 subjects of 2.38±0.66 visits
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traced in 1.56± 0.86 years with only 3 distinct time intervals in month resolution. A
3-D gridded state space with forwarding links is defined such that for each marker,
we have 14 bands that span its value range. The procedure for constructing the state
space and the definition of data emission model is the same as in the Glaucoma exper-
iment. 277 states are instantiated and the model is then trained using Soft(Expm).
The running time using Soft(Expm) is about 17 minutes per iteration on a 2.67 GHz
machine (for comparison, Hard(Unif) is around 2 minutes and Eigen fails.)
The 3D visualization result is shown in Fig. 40. The state transition trends show
that the abnormality of Aβ level emerges first (blue lines) when cognition scores are
still normal. Hippocampus atrophy happens more often (green lines) when Aβ levels
are already low and cognition has started to shown abnormality. Most cognition
degeneration happens (red lines) when both Aβ levels and Hippocampus volume are
already in abnormal stages. Our quantitative visualization results supports the recent
findings that the decreasing of Aβ level in CSF is an early marker before detectable
hippocampus atrophy in cognition-normal elderly [17]. The CT-HMM disease model
armed with 2D/3D interactive visualization functions can be utilized as an exploratory
tool to gain insights of the disease progression and generate hypothesis to be further
investigated by medical researchers.
In the future, we plan to integrate ADNI 1, 2, and GO data [84] so that more
patients in very early disease stages can be included, and more informed disease
progression picture can be derived.
6.1.2 Future directions
Below we list several future directions for further analyzing Alzheimer’s disease:
• 3-D CT-HMM progression models with cluster analysis: For each di-
mension, such as structural, functional, and biochemical, we may also first sum-








Figure 40: 3D CT-HMM analysis by using biochemical measures (amyloid beta),
structural measures (hippocampus volume), and functional measure (ADAS cognition
score), using ADNI1 dataset [84]. The visualization scheme: the strongest transition
link from each state is color coded as follows: Aβ direction only (blue), hippo only
(green), cog only (red), Aβ+hippo (cyan), Aβ+ cog (magenta), hippo+ cog (yellow),
Aβ+hippo+ cog(black). The line width and the node size reflect the expected count.
The node color represents the average sojourn time (red to green: 0 to 3 years and
above).
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and then use these states to define a single dimension. To achieve this, we may
first train a left-to-right HMM using associated measures, and using the learned
mean and covariate to represent the state property in that dimension. This way
we can have a 3-D progression model which is easier to comprehend but much
more measurement types are incorporated in one model.
• CT-HMM with complete graph for event ordering analysis As a prior
work shown in Section 2.3.3, it is of interest to find the atrophy event ordering
of each anatomical area for Alzheimer’s disease. To this end, one idea is as
follows. We can first find clusters from cross-sectional structural measurements
in order to define a set of dominate states. Then, in order to find the temporal
ordering of these states and then derive event ordering, we can model the tem-
poral interactions between these states by using CT-HMM with full pairwise
connections.
• Spatial-temporal CT-HMM for longitudinal image analysis One idea
is to construct a spatial-temporal CT-HMM for capturing the temporal and
spatial interactions of multiple anatomical areas for Alzheimer’s disease. Each
state represents structural properties (e.g., the texture, intensity, thickness,
volume) features, at some time point for one anatomical area. The spatial links
models the spatial relationship (co-occurrence) between anatomical areas. The
temporal links are used to model the temporal structural changes for each area.
By learning the model from a set of manually-segmented longitudinal images,
the CT-HMM captures the dynamic structural changes of each area. This model
can be used for understanding disease evolution directly in image level and can
also be utilized as a time-varying prior for longitudinal image processing tasks,
such as denoising and segmentation.
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6.2 Applications on Hypertension progression modeling us-
ing Electronic Health Data (EHR) data
Hypertension is one of the main risk factors for cardiovascular disease and stroke,
which claim over 17 million lives every year [99]. Several classes of drugs have been
developed to help hypertensive patients maintain normal blood pressure, although the
precise medication regimen needed to achieve blood pressure (BP) control for each
individual is often difficult to determine. As a result, the medication regimen is often
modified on a trial-and-error basis. Long term hypertension management programs
[63] [30] can help participants achieve and maintain controlled blood pressure by en-
couraging regular home monitoring, facilitating medication adjustments and tracking
disease parameters over time in electronic medical records.
Recently, there have been attempts to model hypertension from such electronic
health record (EHR) data. One retrospective study [35] found that including EHR
data improved the performance of regression models and gradient tree boosting for
predicting cardiovascular-related death within 5 years, when compared to models
trained with only traditional risk predictors. Several other studies were also performed
to identify measures that act as risk predictors for the development of hypertension
[53] [9]. However, for the most part these earlier works did not propose any framework
for modeling the longitudinal progression of hypertension in diagnosed individuals.
More recent studies have begun to focus on the prediction of significant events
within hypertension progression. Sun et al. used aggregated EHR data to predict
transitions between controlled and uncontrolled hypertension, and also to identify
which features produced the best prediction performance [80]. This approach, how-
ever, requires constant monitoring of patients hypertension control status in order to
determine the transition at the next clinical encounter. This highlights some of the
difficulties of developing predictive models for hypertension given irregularly timed
patient visits spanning only some segment of the disease progression.
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In order to overcome some of these issues, our work models hypertension as a
hidden continuous-time Markov process evolving on a discrete state space, where
each state is characterized by a certain range of systolic and diastolic blood pressures.
This model structure can represent the continuous evolution of disease states using
measurement data that arrives irregularly in time, and can be used to fill in missing
measurements and predict future trajectories of hypertension evolution. This class of
model is referred to as a continuous time hidden Markov model (CT-HMM) [29] [6]
[52]. It can also be used to study the specific effects of different medication regimens
or individual-level features on hypertension evolution characteristics.
A basic challenge in using data-driven methods to improve healthcare is the de-
velopment of appropriate visualization methods (viz). Viz enables health researchers
to understand and validate a given model and perform exploratory data analysis,
including the generation of hypotheses regarding disease progression. Without viz
there is a danger that models that are fit to complex high dimensional datasets be-
come black box analysis tools whose outputs cannot be explained or interpreted by
health researchers.
Here, we presents FluxMap, the first interactive viz system for displaying and
analyzing state-based disease progressions models based on the CT-HMM framework.
FluxMap is designed to visualize state and transition properties of the CT-HMM and
supports the identification and tracking of sub-groups of patients over time. There
have been a few previous related works: Leiva-Murillo et al. used CT-HMM to model
comorbidity of various diseases over time, illustrating their results using a static
diagram of states and transitions [42]. However, only a small proportion of states and
only the most dominant transitions can be included to avoid visual clutter. Another
group used EventFlow software to look for common patterns in hypertensive drug
usage and relate them to patient outcomes [55] [69]. FluxMap has the potential for
use with any longitudinal state-based progression model, though here we present its
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use in conjunction with a CT-HMM model of hypertension built from longitudinal
EHR data. To the best of our knowledge, this work is the first to demonstrate the
application of an interactive visualization tool to state-based hypertension progression
modeling.
Figure 41: The state and link structure for our hypertension progression model. The
links represent allowed instantaneous transitions with transition intensity qij
6.2.1 2-D exploratory analysis on blood pressure markers
We analyze EHR data from a patient cohort involved in a hypertension management
program. The dataset provides longitudinal data from several patients, each having
a variable number of irregularly timed visits. At each visit, a number of observed
variables are measured, though these measurements may be incomplete in the sense
that not every feature is measured at every time point; for example, lab tests are not
done at every visit. Our hypertension model is based on a 2-dimensional discrete state
space characterized by systolic and diastolic blood pressure range bands. Specifically,
the discrete states are obtained by dividing the continuous space of each dimension
into range bands. This discretization fits well with the typical practice of categorizing
blood pressure using ranges of values. Each state is allowed to instantaneously tran-
sition to its adjacent states, and a qij parameter is to be estimated between each pair
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of source and target state. An illustrative diagram is shown in Fig. 41. Our state-
based model allows flexible transitions between states without assumptions such as
linear or polynomial changes usually used in regression model, and thus is suitable
for exploratory data analysis.
6.2.2 Interactive visualization
In order to convey the results of the CT-HMM model in an easily interpretable way,
we opted for an interactive web-based visualization scheme. The visualization is im-
plemented in JavaScript with the support of D3.js and jQuery libraries. The states are
arranged on a 2D grid layout according to the states systolic and diastolic blood pres-
sure ranges. Each state is represented as a circular node whose radius is proportional
to the number of visits to that state. Transitions between states are bidirectional, so
it was necessary to adopt an edge representation that encodes the direction of flow
between the origin and destination nodes. This is important for being able to identify
key behaviors in BP control like cycles or stable states.
We used asymmetric Bezier curves to depict transitions between states, where
the straight section of the curve is oriented towards the origin node and the more
curved section points towards the destination node. Again, the width and opacity
of each edge are proportional to the number of transitions that occur in the subject
population, to emphasize high-magnitude transitions. This weighting scheme was
chosen over the scaling of edges based on transition intensities for several reasons.
Using transition intensities could cause there to be links between every pair of states,
however small, due to non-zero transition probabilities. The current weighting choice
shows only the trajectories followed by subjects.
The second key component of the visual scheme is its interactivity. First, the user
is allowed to interactively change the subject analysis population through filtering
based on various features, such as medication class, BMI, risk level, lab test results,
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etc. Besides using these standard filters, the subset population may also be chosen
based on some complementary analysis, such as clustering of subjects based on similar
trajectories; such a use case will be discussed shortly. Once a subset of the patient
population is chosen, their collective behavior over the state space can be inspected to
identify major visited states and transitions. Clicking on a particular node highlights
incoming and/or outgoing links with other states by fading out the other nodes and
links slightly. If multiple patient subgroups are selected, the states are depicted as pie
graphs to depict the proportion of measurements from each subgroup. This design is
appropriate for use with a small number of patient subgroups as a means of identifying
any states visited predominantly by one subgroup.
This tool thus enables users to examine the disease progression model in the con-
text of a particular set of features of interest. For example, a user may wish to com-
pare the effects of incorporating different drug classes into a hypertension treatment
regimen on the amount of time spent in controlled-BP states versus uncontrolled-BP
states. To do this, the user simply selects only subjects taking the medications of
interest to be represented in the graph, displaying the states visited and the propor-
tions of each medication class at each one. Hence this visualization scheme combines
an intuitive presentation of the CT-HMM model predictive results with the capacity
for some visual exploratory analysis.
6.2.3 Trajectory clustering results
Trajectory clustering method: to demonstrate the exploratory visual analysis
enabled by our tool, we first trained the CT-HMM on the dataset and produced de-
coded state sequences for all subjects for the window of time they were observed. The
resulting sequences of states were compared between subjects to produce a similar-
ity score based on the weighted Hamming distance. More specifically, the distance
between two states is taken as the number of jumps or edits needed to move from
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(a) Cluster 1 (b) Cluster 2
Figure 42: States and transitions by subjects in cluster 1 and 2 (From [85], used
without permission).
Figure 43: Clusters 1 and 2 shown together.
one state to the other. To compare two sequences, first an alignment is chosen such
that the sequences overlap by at least 3 states; then, the cumulative distance between
overlapping states is found and normalized. Different alignments are tested by sliding
one sequence along the other, and the final similarity score is chosen as the minimum
average distance over all possible alignments. This approach was adopted to account
for the fact that subjects participation in the hypertension management program did
not coincide with any distinctive time point in the progression of their hypertension.
Finally, the subjects trajectories are grouped via hierarchical clustering to obtain
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subsets with similar state sequences.
Clustering result: the above process applied on our dataset produced a hierar-
chical clustering of subjects, with two distinct low-level clusters depicted in Figures
42. Cluster 1 contains 194 subjects with lower diastolic BP on average compared to
the 282 subjects in cluster 2. Further, it appears that subjects in cluster 1 often show
changes in systolic pressure without accompanying changes in diastolic pressure, as
evidenced by the slightly larger weights and numbers of horizontal transitions com-
pared to vertical or diagonal ones. In contrast, subjects in cluster 2 have a noticeably
higher tendency for coupled changes in systolic and diastolic BP, as shown by the
prominent diagonal transitions in Figure 42.
These differences are evident in the combined view using pie charts shown in
Figure 43. By limiting the number of classes to just 2, it is easy to see from the
mostly dark brown nodes with diastolic BP 55 that these states are nearly exclusively
visited by subjects in cluster 1. Similarly, states with diastolic BP 85 and higher are
frequented by subjects in cluster 2 more than cluster 1. It is of interest to further
analyze the characteristics of these two patient groups that may lead to the differences
of BP change dynamics, such as age, occupations, medications, or existence of other
diseases.
6.2.4 Future directions
We have presented an interactive visualization system for disease progression model-
ing using CT-HMM, with the potential for use as a validation tool for the model as
well as an interface for conducting exploratory analysis.
The current visualization scheme has several possibilities for further development.
At present, the identification of true transition sequences (with 2 or more transitions)
is not possible due to the aggregation of transitions across subjects. While the current
approach provides a summary overview of major transitions, it is necessary to include
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some mechanism for recognizing and choosing specific sequences of states that are
visited as part of a major path or cycle. These capabilities will become possible
as the visualization scheme matures. Another possible limitation of the FluxMap
visualization is its limitation to a 2-dimensional state space, whereas the CT-HMM
model for which it was developed can support a higher-dimensional state space. This
disparity can be partly addressed by adopting a side-by-side paneled view, in which
each panel shows a 2D projection or collapse of the ND state space. However, this
drastically reduces the interpretability of the visualization scheme and is untenable
for more than 4 dimensions.
6.3 Conclusion
In this chapter, we use MD CT-HMM as an exploratory tool to analyze and visual-
ize the state transition trends using the key markers from Alzheimer’s disease and
hypertension. For Alzheimer’s disease, our quantitative visualization results using a
3D CT-HMM supports the recent findings that the decreasing of Aβ level in cele-
bral spinal fluid (CSF) is an early marker before detectable hippocampus atrophy in
cognition-normal elderly [17], as the state transition trends show that the abnormal-
ity of Aβ level emerges first when cognition scores are still normal, and Hippocampus
atrophy happens more often when Aβ levels are already low and cognition has started
to shown abnormality.
For hypertension, a 2-D CT-HMM is trained to analyze the dynamic interactions
between two blood pressures: systolic and diastolic. We also present a 2-D interactive
visualization system for disease progression modeling using CT-HMM, with the po-
tential for use as a validation tool for the model as well as an interface for conducting
exploratory analysis. We demonstrated one use case of the tool for viewing states
and trajectories; the case compared subjects from two different subgroups of hyper-
tensive patients obtained by a hierarchical clustering of state sequences decoded by
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the CT-HMM. This visualization framework can be extended to examine more elab-
orate questions related to the effects of different features on the trajectories taken by
subjects. This may be useful for identifying phenotypes or different behaviors within
hypertension management.
In sum, our results show that CT-HMM disease model armed with 2D/3D inter-
active visualization functions can be utilized as an exploratory tool to gain insights of




CONCLUSION AND FUTURE WORK
In this dissertation, we develop multi-dimensional continuous-time hidden Markov
models (M-D CT-HMM) to model disease progression. The continuous-time model
is more suitable for irregularly-sampled temporal data such as clinical measurements
than the discrete-time model. The M-D gridded state structure captures the co-
evolution of multiple disease markers over time, and the learned dynamics among
states can be visualized in a full spectrum of disease progression. Our M-D models
can act as a general exploratory tool which bridges the gap between the simple 1-D
disease staging models used often in clinics and the complex disease-specific models
in research. The findings from using our tools can also be utilized to improve the
design of disease-specific model. We also conduct conceptual comparison of our model
to several existing state-based disease models under different disease contexts and
applications. We find that our model can complement these existing models in flexibly
revealing multi-factor interactions.
To learn large-scale CT-HMM efficiently, we develop novel EM learning algorithms
leveraging the recent findings for CTMC [25] in evaluating the end-state conditioned
expectations. To the best of our knowledge, we present the first comprehensive frame-
work for parameter learning in CT-HMM, which both extends and unifies prior work
on CTMC models. Based on the finite number of observations, our framework dis-
cretizes the estimation of posterior state probabilities into a time-inhomogeneous hid-
den Markov model, and incorporates hard or soft approaches to estimating the hidden
state distributions corresponding to the observations. The benefits and drawbacks of
hard and soft decoding approaches combined with the three different methods (Expm,
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Unif, Eigen) for computing the conditional expectations are analyzed and validated
experimentally. Our results show that soft EM has higher accuracy than hard while
hard EM can save computation time. Expm works well for soft EM approaches while
Unif method may be the best choice in hard EM due to its decomposability in com-
puting only the expectations specified by the two decoded end-states.
We also review the literature in finding the optimal state sequence marginaling
out state dwell time given two end-states and a total time. We augment the state-of-
the-art method in also computing the expected state durations for the optimal state
path. We extend the three expectation evaluation methods (Expm, Unif, Eigen)
in conjunction with a new close-form in computing the path-and-time conditioned
expected state duration with simulation results. These decoding methods can be
utilized in understanding the optimal hidden transition behaviors of a disease or
decoding hidden trajectory of patient data.
We demonstrate the use of M-D CT-HMMs to three disease contexts, Glaucoma,
Alzheimer’s disease, and Hypertension. For Glaucoma, our results using a 2-D CT-
HMM supports the finding in [95] that retinal nerve fiber thickness of around 77
microns acts as a tipping point at which functional deterioration became clinically
observable with structural deterioration. In addition, our 2-D CT-HMM equipped
with a simple procedure to interpolate future continuous measurements gives better
prediction results than the state-of-the art method using Bayesian joint linear regres-
sion [62]. This results show the potential value of M-D CT-HMM for cost-efficient
disease management in clinics. For Alzheimer’s disease, our visualization results of
the learned 3-D CT-HMM support the recent findings that the decreasing of Aβ level
in cerebral spinal fluid is an early marker before detectable hippocampus atrophy in
cognition-normal elderly [17]. For hypertension, a 2-D CT-HMM defined over the
ranges of the two blood pressure types is used. Two distinct patient groups are dis-
covered by using trajectory clustering and the different characteristics can be clearly
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visualized. This demonstrates the use of our model with visualization tool for ex-
ploratory data analysis which can generate new hypotheses such as transition trends
and potential phenotypes to be further investigated by the domain experts.
In sum, we present the first comprehensive framework for parameter learning in
CT-HMM, which both extends and unifies prior work on CTMC models. Our M-D
CT-HMM model paired with visualization tools help capture and comprehend the
possibly complex co-evolution behavior of multiple biomarkers, which can be uti-
lized for predicting future progression trajectories and supporting the identification
of potential phenotypes. This general exploratory tool for disease progression mod-
eling bridges the gap of conventional 1-D disease model and complex disease-specific
model, which has practical value for both clinics and research, leading to cost-effective
disease management and more insights into the underlying mechanism of a disease.
Several future directions include:
(a) Perspective 3D view (b) Projected view using C-mode slicing
Figure 44: Illustration of 3D perspective view and 2D projection view with data
slicing. While it is easy to grasp an overall picture with a 3D perspective view (a),
2D projection view is more suited to detailed exploration of the statistics (b). Users
can switch back and forth between these two views on the fly. The data slicing range
(in this example, the age dimension) can be interactively adjusted.
Interactive visualization tool for M-D CT-HMM: We have developed sev-
eral 2D and 3D visualization tools for M-D CT-HMM which give a global picture of
the progression of a cohort. Dependent variables, such as the number of records in a
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given state and its dwelling time, can be displayed by size and color. Subpopulations
of patients can be identified (e.g. by a common state they visit) and tracked over time.
The distribution of other attributes, such as age, can be visualized at each state (pie
graph view). In order to visualize CT-HMM with greater than 3 dimensions, we can
use 2D projection and range slicing (c-mode slicing). Fig. 44 illustrates interactive
selection of age ranges to update the 2D progression plot in real-time. These tools
can enable medical experts to explore a higher dimensional model and gain insights
into progression within selected data ranges.
Progression phenotypes identification: In Glaucoma disease, existence of
various glaucoma progression phenotypes is an accepted concept among glaucoma
specialists but has never been scientifically and systematically identified yet. M-D
CT-HMM can be utilized to systematically identify potential glaucoma progression
phenotypes by analyzing the learned population-level transition statistics or by group-
ing patients of similar decoded trajectories. The glaucoma experts can examine the
automatically identified phenotypes and analyze whether there are any distinct char-
acteristics of these patient groups. Furthermore, these phenotypes can be utilized
for trajectory-based progression prediction. By training separate CT-HMMs for each
phenotype, we can then classify a given new patient into one phenotype based on
their data history, and perform future trajectory prediction.
The basic idea is to cluster patients into groups based on the similarity of their
progression data. One method from [100] for longitudinal clustering with HMM is to
compute mutual-fitness of the two sequences using the two models trained for each
sequence separately, and do spectral clustering on the resulting similarity matrix,
which can handle differing sequence length and is shown to be robust to noise.
Incorporation of covariate effects in large-scale CT-HMM and estima-
tion of model parameters simultaneously: Besides learning the characteristics
of disease progression using the key disease markers, incorporating and studying the
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Figure 45: The spatial-temporal CT-HMM for longitudinal medical image analysis.
effects of covariates (such as age, race, commorbidities, treatments) in the state tran-
sition rate is also of great clinical interest, which may also result in higher predictive
power. Incorporating the covariate effects to construct individualized transition rate
matrix using cox proportional model is an established method. However, how to es-
timate the weight parameters for these covariates together with learning the baseline
transition rates (when weights are set to zero) appears to be unsolved, and is an
important future work.
M-D CT-HMM / spatial-temporal CT-HMM for longitudinal image
analysis: CT-HMM can be useful for longitudinal medical image analysis. To our
knowledge, it has not been applied to image analysis yet. One intuitive idea is to use
M-D CT-HMMs as a dynamic prior for longitudinal image processing. The discrete
states for structural features can be defined based on training a 1-D left-to-right model
first. The M-D model can then be built for structural, functional, and other aspects.
This model can predict the future state distribution given the current time point,
which can be utilized as a prior in conducting longitudinal image processing.
Another related idea is to construct a spatial-temporal CT-HMM for capturing
the temporal and spatial interactions of multiple anatomical areas (see Fig. 45). Each
state represents structural properties (e.g., the texture, intensity, thickness, volume)
features, at some time point for one anatomical area. The spatial links models the
spatial relationship (co-occurrence) between anatomical areas. The temporal links are
used to model the temporal structural changes for each area. By learning the model
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from a set of manually-segmented longitudinal images, the CT-HMM captures the
dynamic structural changes of each area. This model can be used for understanding
disease evolution directly in image level and can also be utilized as a time-varying
prior for longitudinal image processing tasks, such as denoising and segmentation.
Figure 46: The framework for macular pathology classification in retinal OCT images
from our prior work ([48],[49],[50]
Figure 47: Foveola localization in retinal 3D OCT images using structural support
vector machine from our prior work ([51])
We can apply this idea on modeling longitudinal structural changes in Glaucoma
directly on Optical Coherence Tomography (OCT) images. In pursuing this future
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direction, we can leverage our prior work for automated macular pathology clas-
sification in retinal OCT images ([48],[49],[50] see Fig. 46) and automated foveola
localization in retinal OCT images ([51], see Fig. 47) to automatically do registration
and generate observational features for longitudinal image analysis.
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